

PUBLICATIONS CeRePP / CeRePP PUBLICATIONS

[Cancer de la Prostate et maladies prostatiques \(Etude ProGene\) / Prostate Cancer and prostatic diseases](#) (213)

[Cancer de la Vessie et des Voies Excrétrices Supérieures / Bladder & Upper Urinary Tract Cancer](#) (45)

[Cancer du Rein / Kidney Cancer](#) (14)

Cancer de la Prostate et maladies prostatiques (Etude ProGene) / Prostate

Cancer and prostatic diseases

1. Roperch JP, Charbonnier G, Figiel S, Lamb A, Mills I, Hennion C, Cancel-Tassin G, Cussenot O. Multiple highly methylated CpG sites as potential epigenetic markers for the diagnosis of prostate cancer. *Clin Epigenetics*. 2025 Jul 11;17(1):122. doi: 10.1186/s13148-025-01930-z. PMID: 40646603; PMCID: PMC12247388.
2. Cussenot O. Reply to Hinpetch Daungsupawong and Viroj Wiwanitkit's Letter to the Editor re: Olivier Cussenot, Yoann Taille, Jean-Jacques Portal, et al. Eliciting the Impact of Metformin and Statins on Prostate Cancer Outcomes from a Real-life National Database Analysis. *Eur Urol Oncol*. In press. <https://doi.org/10.1016/j.euo.2025.04.024>. *Eur Urol Oncol*. 2025 Jun 10:S2588-9311(25)00159-2. doi: 10.1016/j.euo.2025.05.016. Epub ahead of print. PMID: 40500603.
3. Cussenot O, Taille Y, Portal JJ, Cancel-Tassin G, Rouprêt M, de la Taille A, Ploussard G, Mathieu R, Vicaut E. Eliciting the Impact of Metformin and Statins on Prostate Cancer Outcomes from a Real-life National Database Analysis. *Eur Urol Oncol*. 2025 Aug;8(4):871-874. doi: 10.1016/j.euo.2025.04.024. Epub 2025 May 9. PMID: 40348654.
4. Matsukawa A, Yanagisawa T, Mischczyk M, Parizi MK, Fazekas T, Tsuboi I, Mancon S, Schulz RJ, Litterio G, Laukhtina E, Rajwa P, Urabe F, Mori K, Miki J, Karakiewicz PI, Chlosta P, Kimura T, Cussenot O, Shariat SF. Incidence and Outcomes of Secondary Bladder Cancer Following Radiation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis. *Eur Urol Focus*. 2025 Jan 22:S2405-4569(24)00262-1. doi: 10.1016/j.euf.2024.12.003. Epub ahead of print. PMID: 39848859.
5. Cussenot O, Poupel L, Mousset C, Lavergne J, Bruyere F, Fontaine A, Cancel-Tassin G, Fromont-Hankard G. Spatial Genomics Identifies Heat Shock Proteins as Key Molecular Changes Associated to Adipose Periprostatic Space Invasion in Prostate Cancer. *Cancers (Basel)*. 2024 Dec 24;17(1):2. doi: 10.3390/cancers17010002. PMID: 39796635; PMCID: PMC11718861.
6. Srinivasan S, Kryza T, Bock N, Tse BWC, Sokolowski KA, Janaththani P, Fernando A, Moya L, Stephens C, Dong Y, Röhl J, Alinezhad S, Vela I, Perry-Keene JL, Buzacott K, Nica R; IMPACT Study; Gago-Dominguez M; PROFILE Study Steering Committee; Schleutker J, Maier C, Muir K, Tangen CM, Gronberg H, Pashayan N, Albanes D, Wolk A, Stanford JL, Berndt SI, Mucci LA, Koutros S, Cussenot O, Sorensen KD, Grindedal EM, Travis RC, Haiman CA, MacInnis RJ, Vega A, Wiklund F, Neal DE, Kogevinas M, Penney KL, Nordestgaard BG, Brenner H, John EM, Gamulin M, Claessens F, Melander O, Dahlin A, Stattin P, Hallmans G, Häggström C, Johansson R, Thysell E, Rönn AC, Li W, Brown N, Dimeski G, Shepherd B, Dadaev T, Brook MN, Spurdle AB, Stenman UH, Koistinen H, Kote-Jarai Z, Klein RJ, Lilja H, Ecker RC, Eeles R; Practical Consortium; Australian Prostate Cancer BioResource; Clements J, Batra J. A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer. *Nat Commun*. 2024 Nov 6;15(1):9587. doi: 10.1038/s41467-024-52472-6. PMID: 39505858; PMCID: PMC11541583.
7. Cussenot O, Chambaz A, Hamdy FC. Re: Annika Herlemann, Janet E. Cowan, Samuel L. Washington 3rd, et al. Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer. *Eur Urol*. 2024;85:565-573. *Eur Urol*. 2024 Aug;86(2):e48-e49. doi: 10.1016/j.eururo.2024.01.030. Epub 2024 Mar 15. PMID: 38492978.
8. Cussenot O, Taille Y, Portal JJ, Cancel-Tassin G, Roupret M, de la Taille A, Ploussard G, Mathieu R, Hamdy FC, Vicaut E. A Comprehensive National Survey of Prostate-specific Antigen Testing and Prostate Cancer Management in France: Uncovering Regional and Temporal Disparities. *Eur Urol Oncol*. 2024 Oct;7(5):978-981. doi: 10.1016/j.euo.2024.02.008. Epub 2024 Mar 11. PMID: 38472031.
9. Yarmolinsky J, Robinson JW, Mariosa D, Karhunen V, Huang J, Dimou N, Murphy N, Burrows K, Bouras E, Smith-Byrne K, Lewis SJ, Galesloot TE, Kiemeny LA, Vermeulen S, Martin P, Albanes D, Hou L, Newcomb PA, White E, Wolk A, Wu AH, Le Marchand L, Phipps AI, Buchanan DD; International Lung Cancer Consortium; PRACTICAL Consortium; Zhao SS, Gill D, Chanock SJ, Purdue MP, Davey Smith G, Brennan P, Herzig KH, Järvelin MR, Amos CI, Hung RJ, Dehghan A, Johansson M, Gunter MJ, Tsilidis KK, Martin RM. Association between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis. *EBioMedicine*. 2024 Feb;100:104991. doi: 10.1016/j.ebiom.2024.104991. Epub 2024 Feb 1. PMID: 38301482; PMCID: PMC10844944.
10. Cussenot O, Timms KM, Perrot E, Blanchet P, Brureau L, Solimeno C, Fromont G, Comperat E, Cancel-Tassin G. Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients. *Eur Urol Oncol*. 2024 Jun;7(3):597-604. doi: 10.1016/j.euo.2023.12.003. Epub 2024 Jan 5. PMID: 38182487.
11. Zambon A, Nguyen TA, Fourcade A, Segalen T, Saout K, Deruelle C, Joulin V, Tissot V, Doucet L, Fournier G, Valeri A. Which protocol for prostate biopsies in patients with a positive MRI? Interest of systematic biopsies by sectors. *Prostate Cancer Prostatic Dis*. 2024 Sep;27(3):500-506. doi: 10.1038/s41391-023-00770-3. Epub 2023 Dec 19. PMID: 38114598.
12. Watts EL, Gonzales TI, Strain T, Saint-Maurice PF, Bishop DT, Chanock SJ, Johansson M, Keku TO, Le Marchand L, Moreno V, Newcomb PA, Newton CC, Pai RK, Purdue MP, Ulrich CM, Smith-Byrne K, Van Guelpen B; PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS; Day FR, Wijndaele K, Wareham NJ, Matthews CE, Moore SC, Brage S. Observational and genetic

- associations between cardiorespiratory fitness and cancer: a UK Biobank and international consortia study. *Br J Cancer*. 2024 Jan;130(1):114-124. doi: 10.1038/s41416-023-02489-3. Epub 2023 Dec 6. PMID: 38057395; PMCID: PMC10781786.
13. Wang A, Shen J, Rodriguez AA, Saunders EJ, Chen F, Janivara R, Darst BF, Sheng X, Xu Y, Chou AJ, Benlloch S, Dadaev T, Brook MN, Plym A, Sahimi A, Hoffman TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Laisk T, Figuerêdo J, Muir K, Ito S, Liu X; Biobank Japan Project; Uchio Y, Kubo M, Kamatani Y, Lophatananon A, Wan P, Andrews C, Lori A, Choudhury PP, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokolorczyk D, Lubinski J, Rentsch CT, Cho K, McMahon BH, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder A, Stroomberg HV, Batra J, Chambers S, Horvath L, Clements JA, Tilly W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordstrom T, Pashayan N, Dunning AM, Ghousaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein S, Cook MB, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM Jr, Hamilton RJ, Fleshner NE, Finelli A, Parent MÉ, Stanford JL, Ostrander EA, Koutros S, Beane Freeman LE, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sørensen KD, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, McDonnell SK, Schaid DJ, West CML, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou YA, John EM, Grindedal EM, Maehle L, Khaw KT, Ingles SA, Stern MC, Vega A, Gómez-Caamaño A, Fachal L, Rosenstein BS, Kerns SL, Ostrer H, Teixeira MR, Paulo P, Brandão A, Watya S, Lubwama A, Bensen JT, Butler EN, Mohler JL, Taylor JA, Kogevinas M, Dierssen-Sotos T, Castaño-Vinyals G, Cannon-Albright L, Teerlink CC, Huff CD, Pilie P, Yu Y, Bohlender RJ, Gu J, Strom SS, Multigner L, Blanchet P, Brureau L, Kaneva R, Slavov C, Mitev V, Leach RJ, Brenner H, Chen X, Holleczer B, Schöttker B, Klein EA, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Kim J, Neuhausen SL, Steele L, Ding YC, Isaacs WB, Nemesure B, Hennis AJM, Carpten J, Pandha H, Michael A, De Ruyck K, De Meerleer G, Ost P, Xu J, Razack A, Lim J, Teo SH, Newcomb LF, Lin DW, Fowke JH, Neslund-Dudas CM, Rybicki BA, Gamulin M, Lessel D, Kulis T, Usmani N, Abraham A, Singhal S, Parliament M, Claessens F, Joniau S, Van den Broeck T, Gago-Dominguez M, Castela JE, Martinez ME, Larkin S, Townsend PA, Aukim-Hastie C, Bush WS, Aldrich MC, Crawford DC, Srivastava S, Cullen J, Petrovics G, Casey G, Wang Y, Tettey Y, Lachance J, Tang W, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Yamoah K, Govindasami K, Chokkalingam AP, Keaton JM, Hellwege JN, Clark PE, Jalloh M, Gueye SM, Niang L, Ogunbiyi O, Shittu O, Amodu O, Adebisi AO, Aisuodionoe-Shadrach OI, Ajibola HO, Jamda MA, Oluwole OP, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Diop H, Gundell SM, Roobol MJ, Jenster G, van Schaik RHN, Hu JJ, Sanderson M, Kachuri L, Varma R, McKean-Cowdin R, Torres M, Preuss MH, Loos RJF, Zawistowski M, Zöllner S, Lu Z, Van Den Eeden SK, Easton DF, Ambis S, Edwards TL, Mägi R, Rebbeck TR, Fritsche L, Chanock SJ, Berndt SI, Wiklund F, Nakagawa H, Witte JS, Gaziano JM, Justice AC, Mancuso N, Terao C, Eeles RA, Kote-Jarai Z, Madduri RK, Conti DV, Haiman CA. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. *Nat Genet*. 2023 Dec;55(12):2065-2074. doi: 10.1038/s41588-023-01534-4. Epub 2023 Nov 9. PMID: 37945903; PMCID: PMC10841479.
14. Valeri A, Nguyen TA. Research on texture images and radiomics in urology: a review of urological MR imaging applications. *Curr Opin Urol*. 2023 Nov 1;33(6):428-436. doi: 10.1097/MOU.0000000000001131. Epub 2023 Sep 18. PMID: 37727910.
15. Gaye O, Fall CB, Jalloh M, Faye B, Jobin M, Cussenot O. Detection of urological cancers by the signature of organic volatile compounds in urine, from dogs to electronic noses. *Curr Opin Urol*. 2023 Nov 1;33(6):437-444. doi: 10.1097/MOU.0000000000001128. Epub 2023 Sep 5. PMID: 37678152.
16. Cancel-Tassin G, Koutros S. Use of genomic markers to improve epidemiologic and clinical research in urology. *Curr Opin Urol*. 2023 Nov 1;33(6):414-420. doi: 10.1097/MOU.0000000000001126. Epub 2023 Aug 29. PMID: 37642472; PMCID: PMC11382258.
17. Cussenot O, Fromont G, Cancel-Tassin G, Hamdy FC, Martin RM. Endemic statistical paradoxes in epidemiologic studies distort knowledge on prostate cancer: mitigation and caution of fallacies in prostate cancer causal epidemiological studies. *Curr Opin Urol*. 2023 Nov 1;33(6):421-427. doi: 10.1097/MOU.0000000000001119. Epub 2023 Aug 13. PMID: 37555785.
18. Cussenot O, Cancel-Tassin G, Rao SR, Woodcock DJ, Lamb AD, Mills IG, Hamdy FC. Aligning germline and somatic mutations in prostate cancer. Are genetics changing practice? *BJU Int*. 2023 Nov;132(5):472-484. doi: 10.1111/bju.16120. Epub 2023 Jul 27. PMID: 37410655.
19. Darst BF, Shen J, Madduri RK, Rodriguez AA, Xiao Y, Sheng X, Saunders EJ, Dadaev T, Brook MN, Hoffmann TJ, Muir K, Wan P, Le Marchand L, Wilkens L, Wang Y, Schleutker J, MacInnis RJ, Cybulski C, Neal DE, Nordestgaard BG, Nielsen SF, Batra J, Clements JA, Cancer BioResource AP, Grönberg H, Pashayan N, Travis RC, Park JY, Albanes D, Weinstein S, Mucci LA, Hunter DJ, Penney KL, Tangen CM, Hamilton RJ, Parent MÉ, Stanford JL, Koutros S, Wolk A, Sørensen KD, Blot WJ, Yeboah ED, Mensah JE, Lu YJ, Schaid DJ, Thibodeau SN, West CM, Maier C, Kibel AS, Cancel-Tassin G, Menegaux F, John EM, Grindedal EM, Khaw KT, Ingles SA, Vega A, Rosenstein BS, Teixeira MR; NC-LA PCaP Investigators; Kogevinas M, Cannon-Albright L, Huff C, Multigner L, Kaneva R, Leach RJ, Brenner H, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Neuhausen SL, Isaacs WB, Nemesure B, Hennis AJ, Carpten J, Pandha H, De Ruyck K, Xu J, Razack A, Teo SH; Canary PASS Investigators; Newcomb LF, Fowke JH, Neslund-Dudas C, Rybicki BA, Gamulin M, Usmani N, Claessens F, Gago-Dominguez M, Castela JE, Townsend PA, Crawford DC, Petrovics G, Casey G, Roobol MJ, Hu JF, Berndt SI, Van Den Eeden SK, Easton DF, Chanock SJ, Cook MB, Wiklund F, Witte JS, Eeles RA, Kote-Jarai Z, Watya S, Gaziano JM, Justice AC, Conti DV, Haiman CA. Evaluating approaches

- for constructing polygenic risk scores for prostate cancer in men of African and European ancestry. *Am J Hum Genet.* 2023 Jul 6;110(7):1200-1206. doi: 10.1016/j.ajhg.2023.05.010. Epub 2023 Jun 12. PMID: 37311464; PMCID: PMC10357473.
20. Tremblay G, Nguyen TA, Marolleau J, Malhaire JP, Fourcade A, Boussion N, Goasduff G, Martin E, Dissaux G, Pradier O, Fournier G, Schick U, Valeri A. Impact of age on the Quadrella index assessing oncological and functional results after prostate brachytherapy: A 6-year analysis. *J Contemp Brachytherapy.* 2023 Apr;15(2):89-95. doi: 10.5114/jcb.2023.127049. Epub 2023 Apr 28. PMID: 37215618; PMCID: PMC10196736.
21. Yarmolinsky J, Bouras E, Constantinescu A, Burrows K, Bull CJ, Vincent EE, Martin RM, Dimopoulou O, Lewis SJ, Moreno V, Vujkovic M, Chang KM, Voight BF, Tsao PS, Gunter MJ, Hampe J, Pellatt AJ, Pharoah PDP, Schoen RE, Gallinger S, Jenkins MA, Pai RK; PRACTICAL consortium; VA Million Veteran Program; Gill D, Tsilidis KK. Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis. *Diabetologia.* 2023 Aug;66(8):1481-1500. doi: 10.1007/s00125-023-05925-4. Epub 2023 May 12. PMID: 37171501; PMCID: PMC10317892.
22. Srinivasan S, Kryza T, Bock N, Tse BW, Sokolowski KA, Panchadsaram J, Moya L, Stephens C, Dong Y, Röhl J, Alinezhad S, Vela I, Perry-Keene JL, Buzacott K; IMPACT Study; Gago-Dominguez M; PROFILE Study Steering Committee; Schleutker J, Maier C, Muir K, Tangen CM, Gronberg H, Pashayan N, Albanes D, Wolk A, Stanford JL, Berndt SI, Mucci LA, Koutros S, Cussenot O, Sorensen KD, Grindedal EM, Key TJ, Haiman CA, Giles GG, Vega A, Wiklund F, Neal DE, Kogevinas M, Stampfer MJ, Nordestgaard BG, Brenner H, Gamulin M, Claessens F, Melander O, Dahlin A, Stattin P, Hallmans G, Häggström C, Johansson R, Thysell E, Rönn AC, Li W, Brown N, Dimeski G, Shepherd B, Dadaev T, Brook MN, Spurdle AB, Stenman UH, Koistinen H, Kote-Jarai Z, Klein RJ, Lilja H, Ecker RC, Eeles R; Practical Consortium; Australian Prostate Cancer BioResource; Clements J, Batra J. Biochemical activity induced by a germline variation in *KLK3* (PSA) associates with cellular function and clinical outcome in prostate cancer. *Res Sq [Preprint].* 2023 Mar 28;rs.3.rs-2650312. doi: 10.21203/rs.3.rs-2650312/v1. Update in: *Nat Commun.* 2024 Nov 6;15(1):9587. doi: 10.1038/s41467-024-52472-6. PMID: 37034758; PMCID: PMC10081352.
23. Chen F, Madduri RK, Rodriguez AA, Darst BF, Chou A, Sheng X, Wang A, Shen J, Saunders EJ, Rhie SK, Bensen JT, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Stanford JL, Zheng W, Sanderson M, John EM, Park JY, Xu J, Wang Y, Berndt SI, Huff CD, Yeboah ED, Tettey Y, Lachance J, Tang W, Rentsch CT, Cho K, McMahon BH, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Sellers TA, Yamoah K, Murphy AB, Crawford DC, Patel AV, Bush WS, Aldrich MC, Cussenot O, Petrovics G, Cullen J, Neslund-Dudas CM, Stern MC, Kote-Jarai Z, Govindasami K, Cook MB, Chokkalingam AP, Hsing AW, Goodman PJ, Hoffmann TJ, Drake BF, Hu JJ, Keaton JM, Hellwege JN, Clark PE, Jalloh M, Gueye SM, Niang L, Ogunbiyi O, Idowu MO, Popoola O, Adebisi AO, Aisuodionoe-Shadrach OI, Ajibola HO, Jamda MA, Oluwole OP, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Mensah JE, Diop H, Van Den Eeden SK, Blanchet P, Fowke JH, Casey G, Hennis AJ, Lubwama A, Thompson IM Jr, Leach R, Easton DF, Preuss MH, Loos RJ, Gundell SM, Wan P, Mohler JL, Fontham ET, Smith GJ, Taylor JA, Srivastava S, Eeles RA, Carpten JD, Kibel AS, Multigner L, Parent MÉ, Menegaux F, Cancel-Tassin G, Klein EA, Andrews C, Rebbeck TR, Brureau L, Ambs S, Edwards TL, Watya S, Chanock SJ, Witte JS, Blot WJ, Michael Gaziano J, Justice AC, Conti DV, Haiman CA. Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry. *Eur Urol.* 2023 Jul;84(1):13-21. doi: 10.1016/j.eururo.2023.01.022. Epub 2023 Mar 3. PMID: 36872133; PMCID: PMC10424812.
24. Cussenot O, Renard-Penna R, Montagne S, Ondet V, Pilon A, Guechot J, Comperat E, Hamdy F, Lamb A, Cancel-Tassin G. Clinical performance of magnetic resonance imaging and biomarkers for prostate cancer diagnosis in men at high genetic risk. *BJU Int.* 2023 Jun;131(6):745-754. doi: 10.1111/bju.15968. Epub 2023 Feb 6. PMID: 36648168.
25. Cussenot O, Cancel-Tassin G, Comperat E, Benbouzid S, Lamb A. Total pelvic exenteration surgery for loco-regionally advanced prostate cancer, is it justifiable? *BJU Int.* 2022 Nov;130(5):582-585. doi: 10.1111/bju.15841. PMID: 36263588.
26. Marolleau J, Nguyen TA, Doucet L, Coste A, Schoentgen N, Rousseau B, Valeri A, Fournier G. Morbidité du curage ganglionnaire pelvien étendu au cours de la prostatectomie totale laparoscopique robot assistée [Morbidity of extended pelvic lymphadenectomy during robot-assisted laparoscopic prostatectomy for localized cancer prostate]. *Prog Urol.* 2022 Dec;32(16):1455-1461. French. doi: 10.1016/j.purol.2022.07.138. Epub 2022 Sep 7. PMID: 36088200.
27. Burns D, Anokian E, Saunders EJ, Bristow RG, Fraser M, Reimand J, Schlomm T, Sauter G, Brors B, Korbel J, Weischenfeldt J, Waszak SM, Corcoran NM, Jung CH, Pope BJ, Hovens CM, Cancel-Tassin G, Cussenot O, Loda M, Sander C, Hayes VM, Dalsgaard Sorensen K, Lu YJ, Hamdy FC, Foster CS, Gnanapragasam V, Butler A, Lynch AG, Massie CE; CR-UK/Prostate Cancer UK, ICGC, The PPCG; Woodcock DJ, Cooper CS, Wedge DC, Brewer DS, Kote-Jarai Z, Eeles RA. Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study. *Eur Urol.* 2022 Aug;82(2):201-211. doi: 10.1016/j.eururo.2022.05.007. Epub 2022 May 31. PMID: 35659150.
28. Abdi B, Basset N, Perrot E, Benderra MA, Khalil A, Oudard S, Blanchet P, Brureau L, Coulet F, Cussenot O, Cancel-Tassin G. DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries. *Prostate.* 2022 Sep;82(12):1196-1201. doi: 10.1002/pros.24374. Epub 2022 Jun 2. PMID: 35652560.
29. Kuhl V, Clegg W, Meek S, Lenz L, Flake DD 2nd, Ronan T, Kornilov M, Horsch D, Scheer M, Farber D, Zalaznick H, Cussenot O, Compérat E, Cancel-Tassin G, Wild PJ, Chun FK, Mandel P, Moinfar F, Cohen T, Delee S, Kronenwett R, Doedt J. Development and validation of a cell cycle progression signature for decentralized testing of men with prostate cancer. *Biomark Med.* 2022 Apr;16(6):449-459. doi: 10.2217/bmm-2021-0479. Epub 2022 Mar 24. PMID: 35321552.

30. Morales Bernstein F, McCartney DL, Lu AT, Tsilidis KK, Bouras E, Haycock PC, Burrows K, Phipps AI, Buchanan DD, Cheng I; PRACTICAL Consortium, Martin RM, Davey Smith G, Relton CL, Horvath S, Marioni RE, Richardson TG, Richmond RC. Assessing the causal role of epigenetic clocks in the development of multiple cancers: a Mendelian randomization study. *Elife*. 2022 Mar 29;11:e75374. doi: 10.7554/eLife.75374. PMID: 35346416.
31. Saout K, Zambon A, Nguyen TA, Lucas C, Payrard-Starck C, Segalen T, Tissot V, Doucet L, Marolleau J, Deruelle C, Joulin V, Fourcade A, Fournier G, Valeri A. Impact of Multiparametric MRI and PSA Density on the Initial Indication or the Maintaining in Active Surveillance During Follow-Up in low-Risk Prostate Cancer. *Clin Genitourin Cancer*. 2022 Jun;20(3):e244-e252. doi: 10.1016/j.clgc.2022.01.015. Epub 2022 Jan 31. PMID: 35216924.
32. Huynh-Le MP, Karunamuni R, Fan CC, Asona L, Thompson WK, Martinez ME, Eeles RA, Kote-Jarai Z, Muir KR, Lophatananon A, Schleutker J, Pashayan N, Batra J, Grönberg H, Neal DE, Nordestgaard BG, Tangen CM, MacInnis RJ, Wolk A, Albanes D, Haiman CA, Travis RC, Blot WJ, Stanford JL, Mucci LA, West CML, Nielsen SF, Kibel AS, Cussenot O, Berndt SI, Koutros S, Sørensen KD, Cybulski C, Grindedal EM, Menegaux F, Park JY, Ingles SA, Maier C, Hamilton RJ, Rosenstein BS, Lu YJ, Watya S, Vega A, Kogevinas M, Wiklund F, Penney KL, Huff CD, Teixeira MR, Multigner L, Leach RJ, Brenner H, John EM, Kaneva R, Logothetis CJ, Neuhausen SL, De Ruyck K, Ost P, Razack A, Newcomb LF, Fowke JH, Gamulin M, Abraham A, Claessens F, Castelao JE, Townsend PA, Crawford DC, Petrovics G, van Schaik RHN, Parent MÉ, Hu JJ, Zheng W; UKGPCS collaborators; APCB (Australian Prostate Cancer BioResource); NC-LA PCaP Investigators; IMPACT Study Steering Committee and Collaborators; Canary PASS Investigators; Profile Study Steering Committee; PRACTICAL Consortium, Mills IG, Andreassen OA, Dale AM, Seibert TM. Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. *Prostate Cancer Prostatic Dis*. 2022 Feb 12. doi: 10.1038/s41391-022-00497-7. Epub ahead of print. PMID: 35152271.
33. Yarmolinsky J, Díez-Obrero V, Richardson TG, Pigeyre M, Sjaarda J, Paré G, Walker VM, Vincent EE, Tan VY, ObónSantacana M, Albanes D, Hampe J, Gsur A, Hampel H, Pai RK, Jenkins M, Gallinger S, Casey G, Zheng W, Amos CI; International Lung Cancer Consortium; PRACTICAL consortium; MEGASTROKE consortium, Smith GD, Martin RM, Moreno V. Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis. *PLoS Med*. 2022 Feb 3;19(2):e1003897. doi: 10.1371/journal.pmed.1003897. PMID: 35113855; PMCID: PMC8812899.
34. Ioannidou A, Watts EL, Perez-Cornago A, Platz EA, Mills IG, Key TJ, Travis RC; PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS, Tsilidis KK, Zuber V. The relationship between lipoprotein A and other lipids with prostate cancer risk: A multivariable Mendelian randomisation study. *PLoS Med*. 2022 Jan 27;19(1):e1003859. doi: 10.1371/journal.pmed.1003859. PMID: 35085228; PMCID: PMC8794090.
35. Bouras E, Karhunen V, Gill D, Huang J, Haycock PC, Gunter MJ, Johansson M, Brennan P, Key T, Lewis SJ, Martin RM, Murphy N, Platz EA, Travis R, Yarmolinsky J, Zuber V, Martin P, Katsoulis M, Freisling H, Nøst TH, Schulze MB, Dossus L, Hung RJ, Amos CI, Ahola-Olli A, Palaniswamy S, Männikkö M, Auvinen J, Herzig KH, KeinänenKiukaanniemi S, Lehtimäki T, Salomaa V, Raitakari O, Salmi M, Jalkanen S; PRACTICAL consortium, Jarvelin MR, Dehghan A, Tsilidis KK. Circulating inflammatory cytokines and risk of five cancers: a Mendelian randomization analysis. *BMC Med*. 2022 Jan 11;20(1):3. doi: 10.1186/s12916-021-02193-0. PMID: 35012533; PMCID: PMC8750876.
36. Darst BF, Hughley R, Pfennig A, Hazra U, Fan C, Wan P, Sheng X, Xia L, Andrews C, Chen F, Berndt SI, Kote-Jarai Z, Govindasami K, Bensen JT, Ingles SA, Rybicki BA, Nemesure B, John EM, Fowke JH, Huff CD, Strom SS, Isaacs WB, Park JY, Zheng W, Ostrander EA, Walsh PC, Carpten J, Sellers TA, Yamoah K, Murphy AB, Sanderson M, Crawford DC, Gapstur SM, Bush WS, Aldrich MC, Cussenot O, Petrovics G, Cullen J, Neslund-Dudas C, Kittles RA, Xu J, Stern MC, Chokkalingam AP, Multigner L, Parent ME, Menegaux F, Cancel-Tassin G, Kibel AS, Klein EA, Goodman PJ, Stanford JL, Drake BF, Hu JJ, Clark PE, Blanchet P, Casey G, Hennis AJM, Lubwama A, Thompson IM Jr, Leach RJ, Gundell SM, Pooler L, Mohler JL, Fontham ETH, Smith GJ, Taylor JA, Brureau L, Blot WJ, Biritwum R, Tay E, Truelove A, Niwa S, Tettey Y, Varma R, McKean-Cowdin R, Torres M, Jalloh M, Magueye Gueye S, Niang L, Ogunbiyi O, Oladimeji Idowu M, Popoola O, Adebisi AO, Aisuodionoe- Shadrach OI, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Yeboah ED, Mensah JE, Anthony Adjei A, Diop H, Cook MB, Chanock SJ, Watya S, Eeles RA, Chiang CWK, Lachance J, Rebbeck TR, Conti DV, Haiman CA. A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry. *Eur Urol*. 2022 Jan 11:S0302-2838(21)02271-5. doi: 10.1016/j.eururo.2021.12.023. Epub ahead of print. PMID: 35031163.
37. Salmon C, Song L, Muir K; UKGPCS Collaborators, Pashayan N, Dunning AM, Batra J; APCB BioResource (Australian Prostate Cancer BioResource), Chambers S, Stanford JL, Ostrander EA, Park JY, Lin HY, Cussenot O, Cancel-Tassin G, Menegaux F, Cordina-Duverger E, Kogevinas M, Llorca J, Kaneva R, Slavov C, Razack A, Lim J, Gago-Dominguez M, Castelao JE, Kote-Jarai Z, Eeles RA; on behalf of the PRACTICAL Consortium, Parent MÉ. Marital status and prostate cancer incidence: a pooled analysis of 12 case-control studies from the PRACTICAL consortium. *Eur J Epidemiol*. 2021 Sep;36(9):913-925. doi: 10.1007/s10654-021-00781-1. Epub 2021 Jul 18. PMID: 34275018.

38. Karlsson Q, Brook MN, Dadaev T, Wakerell S, Saunders EJ, Muir K, Neal DE, Giles GG, MacInnis RJ, Thibodeau SN, McDonnell SK, Cannon-Albright L, Teixeira MR, Paulo P, Cardoso M, Huff C, Li D, Yao Y, Scheet P, Permuth JB, Stanford JL, Dai JY, Ostrander EA, Cussenot O, Cancel-Tassin G, Hoegel J, Herkommer K, Schleutker J, Tammela TLJ, Rathinakannan V, Sipeky C, Wiklund F, Grönberg H, Aly M, Isaacs WB, Dickinson JL, FitzGerald LM, Chua MLK, Nguyen-Dumont T; PRACTICAL Consortium, Schaid DJ, Southey MC, Eeles RA, Kote-Jarai Z. Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. *Eur Urol Oncol*. 2021 Aug;4(4):570-579. doi: 10.1016/j.euo.2020.12.001. Epub 2021 Jan 9. PMID: 33436325; PMCID: PMC8381233.
39. Wang V, Geybels MS, Jordahl KM, Gerke T, Hamid A, Penney KL, Markt SC, Freedman M, Pomerantz M, Lee GM, Rana H, Börnigen D, Rebbeck TR, Huttenhower C, Eeles RA, Stanford JL, PRACTICAL Consortium, Berndt SI, Claessens F, Sørensen KD, Park JY, Vega A, Usmani N, Mucci L, Sweeney CJ. A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. *Prostate*. 2021 Jul;81(10):683-693. doi: 10.1002/pros.24148. PMID: 33956343; PMCID: PMC8491321.
40. Karunamuni RA, Huynh-Le MP, Fan CC, Thompson W, Lui A, Martinez ME, Rose BS, Mahal B, Eeles RA, Kote-Jarai Z, Muir K, Lophatananon A; UKGPCS Collaborators, Tangen CM, Goodman PJ, Thompson IM Jr, Blot WJ, Zheng W, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Park JY, Lin HY, Taylor JA, Bensen JT, Mohler JL, Fontham ETH, Multigner L, Blanchet P, Brureau L, Romana M, Leach RJ, John EM, Fowke JH, Bush WS, Aldrich MC, Crawford DC, Cullen J, Petrovics G, Parent MÉ, Hu JJ, Sanderson M; PRACTICAL Consortium, Mills IG, Andreassen OA, Dale AM, Seibert TM. Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24. *Prostate Cancer Prostatic Dis*. 2021 Jun 14:10.1038/s41391-021-00403-7. doi: 10.1038/s41391-021-00403-7. Epub ahead of print. PMID: 34127801; PMCID: PMC8669040.
41. Lotan TL, Kaur HB, Salles DC, Murali S, Schaeffer EM, Lanchbury JS, Isaacs WB, Brown R, Richardson AL, Cussenot O, Cancel-Tassin G, Timms KM, Antonarakis ES. Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. *Mod Pathol*. 2021 Jun;34(6):1185-1193. doi: 10.1038/s41379-02000731-4. Epub 2021 Jan 18. PMID: 33462368; PMCID: PMC8154637.
42. Karunamuni RA, Huynh-Le MP, Fan CC, Thompson W, Eeles RA, Kote-Jarai Z, Muir K, Lophatananon A; UKGPCS collaborators, Schleutker J, Pashayan N, Batra J; APCB BioResource (Australian Prostate Cancer BioResource), Grönberg H, Walsh EI, Turner EL, Lane A, Martin RM, Neal DE, Donovan JL, Hamdy FC, Nordestgaard BG, Tangen CM, MacInnis RJ, Wolk A, Albanes D, Haiman CA, Travis RC, Stanford JL, Mucci LA, West CML, Nielsen SF, Kibel AS, Wiklund F, Cussenot O, Berndt SI, Koutros S, Sørensen KD, Cybulski C, Grindedal EM, Park JY, Ingles SA, Maier C, Hamilton RJ, Rosenstein BS, Vega A; IMPACT Study Steering Committee and Collaborators, Kogevinas M, Penney KL, Teixeira MR, Brenner H, John EM, Kaneva R, Logothetis CJ, Neuhausen SL, Razack A, Newcomb LF; Canary PASS Investigators, Gamulin M, Usmani N, Claessens F, Gago-Dominguez M, Townsend PA, Roobol MJ, Zheng W; Profile Study Steering Committee, Mills IG, Andreassen OA, Dale AM, Seibert TM; PRACTICAL Consortium. Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. *Prostate Cancer Prostatic Dis*. 2021 Jun;24(2):532-541. doi: 10.1038/s41391-020-00311-2. Epub 2021 Jan 8. PMID: 33420416; PMCID: PMC8157993.
43. Leon P, Cancel-Tassin G, Bourdon V, Buecher B, Oudard S, Brureau L, Jouffe L, Blanchet P, Stoppa-Lyonnet D, Coulet F, Sobol H, Cussenot O. Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer. *Prostate*. 2021 May;81(6):318-325. doi: 10.1002/pros.24109. Epub 2021 Feb 18. PMID: 33599307.
44. Pujol P, Barberis M, Beer P, Friedman E, Piulats JM, Capoluongo ED, Garcia Foncillas J, Ray-Coquard I, PenaultLlorca F, Foulkes WD, Turnbull C, Hanson H, Narod S, Arun BK, Aapro MS, Mandel JL, Normanno N, Lambrechts D, Vergote I, Anahory M, Baertschi B, Baudry K, Bignon YJ, Bollet M, Corsini C, Cussenot O, De la Motte Rouge T, Dubois de Labarre M, Duchamp F, Duriez C, Fizazi K, Galibert V, Gladieff L, Gligorov J, Hammel P, ImbertBouteille M, Jacot W, Kogut-Kubiak T, Lamy PJ, Nambot S, Neuzillet Y, Olschwang S, Rebillard X, Rey JM, Rideau C, Spano JP, Thomas F, Treilleux I, Vandromme M, Vendrell J, Vintraud M, Zarca D, Hughes KS, Alés Martínez JE. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. *Eur J Cancer*. 2021 Mar;146:30-47. doi: 10.1016/j.ejca.2020.12.023. Epub 2021 Feb 10. PMID: 33578357.
45. Compérat E, Renard-Penna R, Ondet V, Cancel-Tassin G, Cussenot O. Diagnosis of prostate cancer in one day: The benefits of cytology in tumour detection. *Cytopathology*. 2021 Mar;32(2):211-216. doi: 10.1111/cyt.12930. Epub 2020 Dec 22. PMID: 33107101.
46. Schaid DJ, McDonnell SK, FitzGerald LM, DeRycke L, Fogarty Z, Giles GG, MacInnis RJ, Southey MC, NguyenDumont T, Cancel-Tassin G, Cussenot O, Whittemore AS, Sieh W, Ioannidis NM, Hsieh CL, Stanford JL, Schleutker J, Cropp CD, Carpten J, Hoegel J, Eeles R, Kote-Jarai Z, Ackerman MJ, Klein CJ, Mandal D, Cooney KA, BaileyWilson JE, Helfand B, Catalona WJ, Wiklund F, Riska S, Bahetti S, Larson MC, Cannon Albright L, Teerlink C, Xu J, Isaacs W, Ostrander EA, Thibodeau SN. Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with

- the Risk of Prostate Cancer. *Eur Urol.* 2021 Mar;79(3):353-361. doi: 10.1016/j.eururo.2020.07.038. Epub 2020 Aug 14. PMID: 32800727; PMCID: PMC7881048.
47. Huynh-Le MP, Fan CC, Karunamuni R, Thompson WK, Martinez ME, Eeles RA, Kote-Jarai Z, Muir K, Schleutker J, Pashayan N, Batra J, Grönberg H, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nielsen SF, Nordestgaard BG, Wiklund F, Tangen CM, Giles GG, Wolk A, Albanes D, Travis RC, Blot WJ, Zheng W, Sanderson M, Stanford JL, Mucci LA, West CML, Kibel AS, Cussenot O, Berndt SI, Koutros S, Sørensen KD, Cybulski C, Grindedal EM, Menegaux F, Khaw KT, Park JY, Ingles SA, Maier C, Hamilton RJ, Thibodeau SN, Rosenstein BS, Lu YJ, Watya S, Vega A, Kogevinas M, Penney KL, Huff C, Teixeira MR, Multigner L, Leach RJ, Cannon-Albright L, Brenner H, John EM, Kaneva R, Logothetis CJ, Neuhausen SL, De Ruyck K, Pandha H, Razack A, Newcomb LF, Fowke JH, Gamulin M, Usmani N, Claessens F, Gago-Dominguez M, Townsend PA, Bush WS, Roobol MJ, Parent MÉ, Hu JJ, Mills IG, Andreassen OA, Dale AM, Seibert TM; UKGPCS collaborators; APCB (Australian Prostate Cancer BioResource); NC-LA PCaP Investigators; IMPACT Study Steering Committee and Collaborators; Canary PASS Investigators; Profile Study Steering Committee; PRACTICAL Consortium. Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. *Nat Commun.* 2021 Feb 23;12(1):1236. doi: 10.1038/s41467-021-21287-0. PMID: 33623038; PMCID: PMC7902617.
48. Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, Schumacher FR, Olama AAA, Benlloch S, Dadaev T, Brook MN, Sahimi A, Hoffmann TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Muir K, Lophatananon A, Wan P, Le Marchand L, Wilkens LR, Stevens VL, Gapstur SM, Carter BD, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokołorczyk D, Lubiński J, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder MA, Iversen P, Batra J, Chambers S, Moya L, Horvath L, Clements JA, Tilley W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordström T, Pashayan N, Dunning AM, Ghousaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein SJ, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM Jr, Hamilton RJ, Fleshner NE, Finelli A, Parent MÉ, Stanford JL, Ostrander EA, Geybels MS, Koutros S, Freeman LEB, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sørensen KD, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, McDonnell SK, Schaid DJ, West CML, Burnet N, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou YA, John EM, Grindedal EM, Maehle L, Khaw KT, Ingles SA, Stern MC, Vega A, Gómez-Caamaño A, Fachal L, Rosenstein BS, Kerns SL, Ostrer H, Teixeira MR, Paulo P, Brandão A, Watya S, Lubwama A, Bensen JT, Fontham ETH, Mohler J, Taylor JA, Kogevinas M, Llorca J, Castaño-Vinyals G, Cannon-Albright L, Teerlink CC, Huff CD, Strom SS, Multigner L, Blanchet P, Brureau L, Kaneva R, Slavov C, Mitev V, Leach RJ, Weaver B, Brenner H, Cuk K, Holleczeck B, Saum KU, Klein EA, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Kim J, Neuhausen SL, Steele L, Ding YC, Isaacs WB, Nemesure B, Hennis AJM, Carpten J, Pandha H, Michael A, De Ruyck K, De Meerleer G, Ost P, Xu J, Razack A, Lim J, Teo SH, Newcomb LF, Lin DW, Fowke JH, Neslund-Dudas C, Rybicki BA, Gamulin M, Lessel D, Kulis T, Usmani N, Singhal S, Parliament M, Claessens F, Joniau S, Van den Broeck T, Gago-Dominguez M, Castela JE, Martinez ME, Larkin S, Townsend PA, Aukim-Hastie C, Bush WS, Aldrich MC, Crawford DC, Srivastava S, Cullen JC, Petrovics G, Casey G, Roobol MJ, Jenster G, van Schaik RHN, Hu JJ, Sanderson M, Varma R, McKean-Cowdin R, Torres M, Mancuso N, Berndt SI, Van Den Eeden SK, Easton DF, Chanock SJ, Cook MB, Wiklund F, Nakagawa H, Witte JS, Eeles RA, Kote-Jarai Z, Haiman CA. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. *Nat Genet.* 2021 Jan;53(1):65-75.
49. Karunamuni RA, Huynh-Le MP, Fan CC, Thompson W, Eeles RA, Kote-Jarai Z, Muir K; UKGPCS Collaborators, Lophatananon A, Tangen CM, Goodman PJ, Thompson IM Jr, Blot WJ, Zheng W, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Park JY, Lin HY, Bensen JT, Fontham ETH, Mohler JL, Taylor JA, Multigner L, Blanchet P, Brureau L, Romana M, Leach RJ, John EM, Fowke J, Bush WS, Aldrich M, Crawford DC, Srivastava S, Cullen JC, Petrovics G, Parent MÉ, Hu JJ, Sanderson M, Mills IG, Andreassen OA, Dale AM, Seibert TM; PRACTICAL Consortium. African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. *Int J Cancer.* 2021 Jan 1;148(1):99-105.
50. Wendeu-Foyet MG, Cénée S, Koudou Y, Trétarre B, Rébillard X, Cancel-Tassin G, Cussenot O, Boland A, Olaso R, Deleuze JF, Blanché H, Lamy PJ, Mulot C, Laurent-Puig P, Truong T, Menegaux F. Circadian genes polymorphisms, night work and prostate cancer risk: Findings from the EPICAP study. *Int J Cancer.* 2020 Dec 1;147(11):31193129.
51. Pinar U, Cancel-Tassin G, Renard-Penna R, Ayadi M, Ondet V, Gaffory C, Clery R, Comperat E, Roupert M, De Reynies A, Cussenot O. Apport prédictif d'une signature moléculaire à la classification pronostique CAPRA des cancers de prostate avant prostatectomie radicale. *Prog Urol.* 2020 Nov;30(13):775.
52. Compérat E, Wasinger G, Oszwald A, Kain R, Cancel-Tassin G, Cussenot O. The Genetic Complexity of Prostate Cancer. *Genes (Basel).* 2020 Nov 25;11(12):1396.
53. Brandão A, Paulo P, Maia S, Pinheiro M, Peixoto A, Cardoso M, Silva MP, Santos C, Eeles RA, Kote-Jarai Z, Muir K, Ukgpcs Collaborators, Schleutker J, Wang Y, Pashayan N, Batra J, Apbc BioResource, Grönberg H, Neal DE, Nordestgaard BG, Tangen

- CM, Southey MC, Wolk A, Albanes D, Haiman CA, Travis RC, Stanford JL, Mucci LA, West CML, Nielsen SF, Kibel AS, Cussenot O, Berndt SI, Koutros S, Sørensen KD, Cybulski C, Grindedal EM, Park JY, Ingles SA, Maier C, Hamilton RJ, Rosenstein BS, Vega A, The Impact Study Steering Committee And Collaborators, Kogevinas M, Wiklund F, Penney KL, Brenner H, John EM, Kaneva R, Logothetis CJ, Neuhausen SL, Ruyck K, Razack A, Newcomb LF, Canary Pass Investigators, Lessel D, Usmani N, Claessens F, Gago-Dominguez M, Townsend PA, Roobol MJ, The Profile Study Steering Committee, The Practical Consortium, Teixeira MR. The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. *Cancers (Basel)*. 2020 Nov 4;12(11):3254.
54. Darst BF, Wan P, Sheng X, Bensen JT, Ingles SA, Rybicki BA, Nemesure B, John EM, Fowke JH, Stevens VL, Berndt SI, Huff CD, Strom SS, Park JY, Zheng W, Ostrander EA, Walsh PC, Srivastava S, Carpten J, Sellers TA, Yamoah K, Murphy AB, Sanderson M, Crawford DC, Gapstur SM, Bush WS, Aldrich MC, Cussenot O, Yeager M, Petrovics G, Cullen J, Neslund-Dudas C, Kittles RA, Xu J, Stern MC, Kote-Jarai Z, Govindasami K, Chokkalingam AP, Multigner L, Parent ME, Menegaux F, Cancel-Tassin G, Kibel AS, Klein EA, Goodman PJ, Drake BF, Hu JJ, Clark PE, Blanchet P, Casey G, Hennis AJM, Lubwama A, Thompson IM Jr, Leach R, Gundell SM, Pooler L, Xia L, Mohler JL, Fontham ETH, Smith GJ, Taylor JA, Eeles RA, Brureau L, Chanock SJ, Watya S, Stanford JL, Mandal D, Isaacs WB, Cooney K, Blot WJ, Conti DV, Haiman CA. A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. *Eur Urol*. 2020 Sep;78(3):316-320.
55. Peigne C, Fournier G, Dissaux G, Delage F, Coquet JB, Boussion N, Goasduff G, Malhaire JP, Pradier O, Schick U, Valeri A. Minimal channel GreenLight photovaporization before permanent implant prostate brachytherapy for patients with obstructive symptoms: Technically feasible and safe. *Brachytherapy*. 2020 Sep 2:S15384721(20)30178-1.
56. Schaid DJ, McDonnell SK, FitzGerald LM, DeRycke L, Fogarty Z, Giles GG, MacInnis RJ, Southey MC, NguyenDumont T, Cancel-Tassin G, Cussenot O, Whittemore AS, Sieh W, Ioannidis NM, Hsieh CL, Stanford JL, Schleutker J, Cropp CD, Carpten J, Hoegel J, Eeles R, Kote-Jarai Z, Ackerman MJ, Klein CJ, Mandal D, Cooney KA, BaileyWilson JE, Helfand B, Catalona WJ, Wiklund F, Riska S, Bahetti S, Larson MC, Cannon Albright L, Teerlink C, Xu J, Isaacs W, Ostrander EA, Thibodeau SN. Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. *Eur Urol*. 2020 Aug 13:S0302-2838(20)30614-X.
57. Wu L, Yang Y, Guo X, Shu XO, Cai Q, Shu X, Li B, Tao R, Wu C, Nikas JB, Sun Y, Zhu J, Roobol MJ, Giles GG, Brenner H, John EM, Clements J, Grindedal EM, Park JY, Stanford JL, Kote-Jarai Z, Haiman CA, Eeles RA, Zheng W, Long J; PRACTICAL consortium; CRUK Consortium; BPC3 Consortium; CAPS Consortium; PEGASUS Consortium. An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk. *Nat Commun*. 2020 Aug 6;11(1):3905.
58. Lenfant L, Leon P, Cancel-Tassin G, Audouin M, Staerman F, Rouprêt M, Cussenot O. Testosterone replacement therapy (TRT) and prostate cancer: An updated systematic review with a focus on previous or active localized prostate cancer. *Urol Oncol*. 2020 Aug;38(8):661-670.
59. Ahmed M, Goh C, Saunders E, Cieza-Borrella C; PRACTICAL consortium, Kote-Jarai Z, Schumacher FR, Eeles R. Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT. *Prostate Cancer Prostatic Dis*. 2020 Jun;23(2):333-342.
60. Zhang-Yin J, Provost C, Cancel-Tassin G, Rusu T, Penent M, Radulescu C, Comperat E, Cussenot O, Montravers F, Renard-Penna R, Talbot JN, Prignon A. A comparative study of peptide-based imaging agents [68Ga]Ga-PSMA11, [68Ga]Ga-AMBA, [68Ga]Ga-NODAGA-RGD and [68Ga]Ga-DOTA-NT-20.3 in preclinical prostate tumour models. *Nucl Med Biol*. 2020 May-Jun;84-85:88-95.
61. Thompson DJ, Genovese G, Halvardson J, Ulirsch JC, Wright DJ, Terao C, Davidsson OB, Day FR, Sulem P, Jiang Y, Danielsson M, Davies H, Dennis J, Dunlop MG, Easton DF, Fisher VA, Zink F, Houlston RS, Ingelsson M, Kar S, Kerrison ND, Kinnersley B, Kristjansson RP, Law PJ, Li R, Loveday C, Mattisson J, McCarroll SA, Murakami Y, Murray A, Olszewski P, Rychlicka-Buniowska E, Scott RA, Thorsteinsdottir U, Tomlinson I, Moghadam BT, Turnbull C, Wareham NJ, Gudbjartsson DF; International Lung Cancer Consortium (INTEGRAL-ILCCO); Breast Cancer Association Consortium; Consortium of Investigators of Modifiers of BRCA1/2; Endometrial Cancer Association Consortium; Ovarian Cancer Association Consortium; Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) Consortium; Kidney Cancer GWAS MetaAnalysis Project; eQTLGen Consortium; Biobank-based Integrative Omics Study (BIOS) Consortium; 23andMe Research Team, Kamatani Y, Hoffmann ER, Jackson SP, Stefansson K, Auton A, Ong KK, Machiela MJ, Loh PR, Dumanski JP, Chanock SJ, Forsberg LA, Perry JRB. Genetic predisposition to mosaic Y chromosome loss in blood. *Nature*. 2019 Nov;575(7784):652-657. doi: 10.1038/s41586-019-1765-3.
62. Wendeu-Foyet MG, Koudou Y, Cénée S, Trétarre B, Rébillard X, Cancel-Tassin G, Cussenot O, Boland A, Bacq D, Deleuze JF, Lamy PJ, Mulot C, Laurent-Puig P, Truong T, Menegaux F. Circadian genes and risk of prostate cancer: Findings from the EPICAP study. *Int J Cancer*. 2019 Oct 1;145(7):1745-1753.

63. Jiang X, Dimou NL, Al-Dabhani K, Lewis SJ, Martin RM, Haycock PC, Gunter MJ, Key TJ, Eeles RA, Muir K, Neal D, Giles GG, Giovannucci EL, Stampfer M, Pierce BL, Schildkraut JM, Warren Andersen S, Thompson D, Zheng W, Kraft P, Tsilidis KK; PRACTICAL, CRUK, BPC3, CAPS and PEGASUS consortia. Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study. *Int J Epidemiol*. 2019 Oct 1;48(5):1416-1424.
64. Wu L, Shu X, Bao J, Guo X, Kote-Jarai Z, Haiman CA, Eeles RA, Zheng W; PRACTICAL, CRUK, BPC3, CAPS, PEGASUS Consortia. Analysis of Over 140,000 European Descendants Identifies Genetically Predicted Blood Protein Biomarkers Associated with Prostate Cancer Risk. *Cancer Res*. 2019 Sep 15;79(18):4592-4598.
65. Wu L, Wang J, Cai Q, Cavazos TB, Emami NC, Long J, Shu XO, Lu Y, Guo X, Bauer JA, Pasaniuc B, Penney KL, Freedman ML, Kote-Jarai Z, Witte JS, Haiman CA, Eeles RA, Zheng W; PRACTICAL, CRUK, BPC3, CAPS, PEGASUS Consortia. Identification of Novel Susceptibility Loci and Genes for Prostate Cancer Risk: A Transcriptome-Wide Association Study in Over 140,000 European Descendants. *Cancer Res*. 2019 Jul 1;79(13):3192-3204.
66. Schoentgen N, Marolleau J, Delage F, Coquet JB, Fourcade A, Callerot P, Serey-Eiffel S, Malhaire JP, Pradier O, Schick U, Fournier G, Valeri A. Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 > 16. *J Contemp Brachytherapy*. 2019 Jun;11(3):195-200.
67. Beynon RA, Richmond RC, Santos Ferreira DL, Ness AR, May M, Smith GD, Vincent EE, Adams C, Ala-Korpela M, Würtz P, Soidinsalo S, Metcalfe C, Donovan JL, Lane AJ, Martin RM; ProtecT Study Group; PRACTICAL consortium. Investigating the effects of lycopene and green tea on the metabolome of men at risk of prostate cancer: The ProDiet randomised controlled trial. *Int J Cancer*. 2019 Apr 15;144(8):1918-1928.
68. Adams CD, Richmond R, Ferreira DLS, Spiller W, Tan V, Zheng J, Würtz P, Donovan J, Hamdy F, Neal D, Lane JA, Smith GD, Relton C, Eeles RA, Haiman CA, Kote-Jarai Z, Schumacher FR, Olama AAA, Benlloch S, Muir K, Berndt SI, Conti DV, Wiklund F, Chanock SJ, Gapstur S, Stevens VL, Tangen CM, Batra J, Clements JA, Gronberg H, Pashayan N, Schleutker J, Albanes D, Wolk A, West CML, Mucci LA, Cance-Tassin G, Koutros S, Sorensen KD, Maehle L, Travis RC, Hamilton RJ, Ingles SA, Rosenstein BS, Lu YJ, Giles GG, Kibel AS, Vega A, Kogevinas M, Penney KL, Park JY, Stanford JL, Cybulski C, Nordestgaard BG, Brenner H, Maier C, Kim J, John EM, Teixeira MR, Neuhausen SL, De Ruyck K, Razack A, Newcomb LF, Llessel D, Kaneva RP, Usmani N, Claessens F, Townsend PA, Dominguez MG, Roobol MJ, Menegaux F, Khaw KT, Cannon-Albright LA, Pandha H, Thibodeau SN, Martin RM; PRACTICAL consortium. Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. *Cancer Epidemiol Biomarkers Prev*. 2019 Jan;28(1):208-216.
69. Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesueur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Batra J, Beckmann MW, Benitez J, Benlloch S, Berchuck A, Berndt SI, Bickeböller H, Bien SA, Blomqvist C, Boccia S, Bogdanova NV, Bojesen SE, Bolla MK, Brauch H, Brenner H, Brenton JD, Brook MN, Brunet J, Brunnström H, Buchanan DD, Burwinkel B, Butzow R, Cadoni G, Caldés T, Caligo MA, Campbell I, Campbell PT, Cance-Tassin G, Cannon-Albright L, Campa D, Caporaso N, Carvalho AL, Chan AT, Chang-Claude J, Chanock SJ, Chen C, Christiani DC, Claes KBM, Claessens F, Clements J, Collée JM, Correa MC, Couch FJ, Cox A, Cunningham JM, Cybulski C, Czene K, Daly MB, deFazio A, Devilee P, Diez O, Gago-Dominguez M, Donovan JL, Dörk T, Duell EJ, Dunning AM, Dwek M, Eccles DM, Edlund CK, Edwards DRV, Ellberg C, Evans DG, Fasching PA, Ferris RL, Liloglou T, Figueiredo JC, Fletcher O, Fortner RT, Fostira F, Franceschi S, Friedman E, Gallinger SJ, Ganz PA, Garber J, García-Sáenz JA, Gayther SA, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, Goode EL, Goodman MT, Goodman G, Grankvist K, Greene MH, Gronberg H, Gronwald J, Guénel P, Håkansson N, Hall P, Hamann U, Hamdy FC, Hamilton RJ, Hampe J, Haugen A, Heitz F, Herrero R, Hillemanns P, Hoffmeister M, Høgdall E, Hong YC, Hopper JL, Houlston R, Hulick PJ, Hunter DJ, Huntsman DG, Idos G, Ilyanov EN, Ingles SA, Isaacs C, Jakubowska A, James P, Jenkins MA, Johansson M, Johansson M, John EM, Joshi AD, Kaneva R, Karlan BY, Kelemen LE, Köhl T, Khaw KT, Khusnutdinova E, Kibel AS, Kiemeny LA, Kim J, Kjaer SK, Knight JA, Kogevinas M, Kote-Jarai Z, Koutros S, Kristensen VN, Kupryjanczyk J, Lacko M, Lam S, Lambrechts D, Landi MT, Lazarus P, Le ND, Lee E, Lejbkiewicz F, Lenz HJ, Leslie G, Llessel D, Lester J, Levine DA, Li L, Li CI, Lindblom A, Lindor NM, Liu G, Llopakis F, Lubinski J, Maehle L, Maier C, Mannermaa A, Marchand LL, Margolin S, May T, McGuffog L, Meindl A, Middha P, Miller A, Milne RL, MacInnis RJ, Modugno F, Montagna M, Moreno V, Moysich KB, Mucci L, Muir K, Mulligan AM, Nathanson KL, Neal DE, Ness AR, Neuhausen SL, Nevanlinna H, Newcomb PA, Newcomb LF, Nielsen FC, Nikitina-Zake L, Nordestgaard BG, Nussbaum RL, Offit K, Olah E, Olama AAA, Olopade OI, Olshan AF, Olsson H, Osorio A, Pandha H, Park JY, Pashayan N, Parsons MT, Pejovic T, Penney KL, Peters WHM, Phelan CM, Phipps AI, Plaseska-Karanfilska D, Pring M, Prokofyeva D, Radice P, Stefansson K, Ramus SJ, Raskin L, Rennert G, Rennert HS, van Rensburg EJ, Riggan MJ, Risch HA, Risch A, Roobol MJ, Rosenstein BS, Rossing MA, De Ruyck K, Saloustros E, Sandler DP, Sawyer EJ, Schabath MB, Schleutker J, Schmidt MK, Setiawan VW, Shen H, Siegel EM, Sieh W, Singer CF, Slatery ML, Sorensen KD, Southey MC, Spurdle AB, Stanford JL, Stevens VL, Stintzing S, Stone J, Sundfeldt K, Sutphen R, Swerdlow AJ, Tajara EH, Tangen CM, Tardon A, Taylor JA, Teare MD, Teixeira MR, Terry MB, Terry KL, Thibodeau SN, Thomassen M, Bjørge L, Tischkowitz M, Toland AE, Torres D, Townsend PA, Travis

- RC, Tung N, Tworoger SS, Ulrich CM, Usmani N, Vachon CM, Van Nieuwenhuysen E, Vega A, AguadoBarrera ME, Wang Q, Webb PM, Weinberg CR, Weinstein S, Weissler MC, Weitzel JN, West CML, White E, Whittemore AS, Wichmann HE, Wiklund F, Winqvist R, Wolk A, Woll P, Woods M, Wu AH, Wu X, Yannoukakos D, Zheng W, Zienolddiny S, Ziogas A, Zorn KK, Lane JM, Saxena R, Thomas D, Hung RJ, Diergaarde B, McKay J, Peters U, Hsu L, García-Closas M, Eeles RA, Chenevix-Trench G, Brennan PJ, Haiman CA, Simard J, Easton DF, Gruber SB, Pharoah PDP, Price AL, Pasaniuc B, Amos CI, Kraft P, Lindström S. Shared heritability and functional enrichment across six solid cancers. *Nat Commun*. 2019 Jan 25;10(1):431. Erratum in: *Nat Commun*. 2019 Sep 23;10(1):4386.
70. Srinivasan S, Stephens C, Wilson E, Panchadsaram J, DeVoss K, Koistinen H, Stenman UH, Brook MN, Buckle AM, Klein RJ, Lilja H, Clements J, Batra J; Practical Consortium. Prostate Cancer Risk-Associated Single-Nucleotide Polymorphism Affects Prostate-Specific Antigen Glycosylation and Its Function. *Clin Chem*. 2019 Jan;65(1):e1e9.
71. Tonon L, Fromont G, Boyault S, Thomas E, Ferrari A, Sertier AS, Kielbassa J, Le Texier V, Kamoun A, Elarouci N, Irani J, Multigner L, Gut IG, Gut M, Blanchet P, De Reynies A, Cancel-Tassin G, Viari A, Cussenot O. Mutational Profile of Aggressive, Localised Prostate Cancer from African Caribbean Men Versus European Ancestry Men. *Eur Urol*. 2019 Jan;75(1):11-15.
72. Tan VY, Biernacka KM, Dudding T, Bonilla C, Gilbert R, Kaplan RC, Qibin Q, Teumer A, Martin RM, Perks CM, Timpson NJ, Holly JMP; PRACTICAL consortium. Reassessing the Association between Circulating Vitamin D and IGFBP-3: Observational and Mendelian Randomization Estimates from Independent Sources. *Cancer Epidemiol Biomarkers Prev*. 2018 Dec;27(12):1462-1471.
73. Matejic M, Saunders EJ, Dadaev T, Brook MN, Wang K, Sheng X, Olama AAA, Schumacher FR, Ingles SA, Govindasami K, Benlloch S, Berndt SI, Albanes D, Koutros S, Muir K, Stevens VL, Gapstur SM, Tangen CM, Batra J, Clements J, Gronberg H, Pashayan N, Schleutker J, Wolk A, West C, Mucci L, Kraft P, Cancel-Tassin G, Sorensen KD, Maehle L, Grindedal EM, Strom SS, Neal DE, Hamdy FC, Donovan JL, Travis RC, Hamilton RJ, Rosenstein B, Lu YJ, Giles GG, Kibel AS, Vega A, Bensen JT, Kogevinas M, Penney KL, Park JY, Stanford JL, Cybulski C, Nordestgaard BG, Brenner H, Maier C, Kim J, Teixeira MR, Neuhausen SL, De Ruyck K, Razack A, Newcomb LF, Llessel D, Kaneva R, Usmani N, Claessens F, Townsend PA, Dominguez MG, Roobol MJ, Menegaux F, Khaw KT, Cannon-Albright LA, Pandha H, Thibodeau SN, Schaid DJ; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Wiklund F, Chanock SJ, Easton DF, Eeles RA, Kote-Jarai Z, Conti DV, Haiman CA. Germline variation at 8q24 and prostate cancer risk in men of European ancestry. *Nat Commun*. 2018 Nov 5;9(1):4616.
74. Yarmolinsky J, Berryman K, Langdon R, Bonilla C; PRACTICAL consortium, Davey Smith G, Martin RM, Lewis SJ. Mendelian randomization does not support serum calcium in prostate cancer risk. *Cancer Causes Control*. 2018 Nov;29(11):1073-1080.
75. Kaikkonen E, Rantapero T, Zhang Q, Taimen P, Laitinen V, Kallajoki M, Jambulingam D, Ettala O, Knaapila J, Boström PJ, Wahlström G, Sipeky C, Pursiheimo JP, Tammela T, Kellokumpu-Lehtinen PL; PRACTICAL Consortium, Fey V, Maehle L, Wiklund F, Wei GH, Schleutker J. ANO7 is associated with aggressive prostate cancer. *Int J Cancer*. 2018 Nov 15;143(10):2479-2487.
76. Rozet F, Hennequin C, Beauval JB, Beuzeboc P, Cormier L, Fromont-Hankard G, Mongiat-Artus P, Ploussard G, Mathieu R, Brureau L, Ouzzane A, Azria D, Brenot-Rossi I, Cancel-Tassin G, Cussenot O, Rebillard X, Lebrete T, Soulié M, Renard Penna R, Méjean A. French ccAFU guidelines - Update 2018-2020: Prostate cancer. *Prog Urol*. 2018 Nov;28 Suppl 1:R81-R132.
77. Mancuso N, Gayther S, Gusev A, Zheng W, Penney KL, Kote-Jarai Z, Eeles R, Freedman M, Haiman C, Pasaniuc B; PRACTICAL consortium. Large-scale transcriptome-wide association study identifies new prostate cancer risk regions. *Nat Commun*. 2018 Oct 4;9(1):4079. Erratum in: *Nat Commun*. 2019 Jan 8;10(1):171.
78. Coquet JB, Delage F, Fourcade A, Callerot P, Goasduff G, Boussion N, Rousseau B, Serey-Eiffel S, Malhaire JP, Pradier O, Schick U, Fournier G, Valeri A. Evaluation of the "Quadrella" at 3 years: New index to assess functional and oncological performance specific to prostate brachytherapy. *Brachytherapy*. 2018 Sep - Oct;17(5):782-787.
79. Yarmolinsky J, Bonilla C, Haycock PC, Langdon RJQ, Lotta LA, Langenberg C, Relton CL, Lewis SJ, Evans DM; PRACTICAL Consortium, Davey Smith G, Martin RM. Circulating Selenium and Prostate Cancer Risk: A Mendelian Randomization Analysis. *J Natl Cancer Inst*. 2018 Sep 1;110(9):1035-1038.
80. Léon P, Cancel-Tassin G, Drouin S, Audouin M, Varinot J, Comperat E, Cathelineau X, Rozet F, Vaessens C, Stone S, Reid J, Sangale Z, Korman P, Rouprêt M, Fromond-Hankard G, Cussenot O. Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy. *World J Urol*. 2018 Sep;36(9):1495-1500.
81. Kamoun A, Cancel-Tassin G, Fromont G, Elarouci N, Armenoult L, Ayadi M, Irani J, Leroy X, Villers A, Fournier G, Doucet L, Boyault S, Brureau L, Multigner L, Diedhiou A, Roupret M, Compérat E, Blanchet P, de Reynies A, Cussenot O. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. *Ann Oncol*. 2018 Aug 1;29(8):1814-1821.

82. Wendeu-Foyet MG, Bayon V, C  n  e S, Tr  tarre B, R  billard X, Cancel-Tassin G, Cussenot O, Lamy PJ, Faraut B, Ben Khedher S, L  ger D, Menegaux F. Night work and prostate cancer risk: results from the EPICAP Study. *Occup Environ Med.* 2018 Aug;75(8):573-581.
83. Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordstr  m T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, H  kansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, G  mez-Caama  o A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Casta  o-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, R  der MA, Iversen P, Brenner H, Cuk K, Holleczeck B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Dominguez MG, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA; Profile Study, Xu J, Khaw KT, CannonAlbright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genomewide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nat Genet.* 2018 Jul;50(7):928-936. Erratum in: *Nat Genet.* 2019 Feb;51(2):363.
84. Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordstr  m T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, G  mez-Caama  o A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Casta  o-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weisher M, Bisbjerg R, R  der MA, Iversen P, Brenner H, Cuk K, Holleczeck B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Kraft P; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Freedman M, Wiklund F, Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, Kote-Jarai Z. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. *Nat Commun.* 2018 Jun 11;9(1):2256.
85. Tavolaro S, Mozer P, Roupret M, Comperat E, Rozet F, Barret E, Drouin S, Vaessen C, Lucidarme O, Cussenot O, Boudgh  ne F, Renard-Penna R. Transition zone and anterior stromal prostate cancers: Evaluation of discriminant location criteria using multiparametric fusion-guided biopsy. *Diagn Interv Imaging.* 2018 Jun;99(6):403-411.
86. Fourcade A, Payrard C, Tissot V, Perrouin-Verbe MA, Demany N, Serey-Effeil S, Callerot P, Coquet JB, Doucet L, Deruelle C, Joulin V, Nonent M, Fournier G, Valeri A. The combination of targeted and systematic prostate biopsies is the best protocol for the detection of clinically significant prostate cancer. *Scand J Urol.* 2018 Jun;52(3):174-179.

87. Monnier L, Culine S, Cormier L. Les traitements combinés dans les formes à haut risque évolutif du cancer de la prostate (localisé ou non). *Presse Med.* 2017 Oct;46(10):940-947.
88. Conti DV, Wang K, Sheng X, Bensen JT, Hazelett DJ, Cook MB, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Stanford JL, Zheng W, Sanderson M, John EM, Park JY, Xu J, Stevens VL, Berndt SI, Huff CD, Wang Z, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Sellers TA, Yamoah K, Murphy AB, Crawford DC, Gapstur SM, Bush WS, Aldrich MC, Cussenot O, Petrovics G, Cullen J, Neslund-Dudas C, Stern MC, Jarai ZK, Govindasami K, Chokkalingam AP, Hsing AW, Goodman PJ, Hoffmann T, Drake BF, Hu JJ, Clark PE, Van Den Eeden SK, Blanchet P, Fowke JH, Casey G, Hennis AJM, Han Y, Lubwama A, Thompson IM Jr, Leach R, Easton DF, Schumacher F, Van den Berg DJ, Gundell SM, Stram A, Wan P, Xia L, Pooler LC, Mohler JL, Fonham ETH, Smith GJ, Taylor JA, Srivastava S, Eeles RA, Carpten J, Kibel AS, Multigner L, Parent ME, Menegaux F, Cancel-Tassin G, Klein EA, Brureau L, Stram DO, Watya S, Chanock SJ, Witte JS, Blot WJ, Henderson BE, Haiman CA; PRACTICAL/ELLIPSE Consortium. Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. *J Natl Cancer Inst.* 2017 Aug 1;109(8):dx084.
89. Larson NB, McDonnell S, Cannon Albright L, Teerlink C, Stanford J, Ostrander EA, Isaacs WB, Xu J, Cooney KA, Lange E, Schleutker J, Carpten JD, Powell I, Bailey-Wilson JE, Cussenot O, Cancel-Tassin G, Giles GG, MacInnis RJ, Maier C, Whittemore AS, Hsieh CL, Wiklund F, Catalona WJ, Foulkes W, Mandal D, Eeles R, Kote-Jarai Z, Ackerman MJ, Olson TM, Klein CJ, Thibodeau SN, Schaid DJ. gsSKAT: Rapid gene set analysis and multiple testing correction for rare-variant association studies using weighted linear kernels. *Genet Epidemiol.* 2017 May;41(4):297-308. Erratum in: *Genet Epidemiol.* 2017 Nov;41(7):710.
90. Marin L, Eziane M, Comperat E, Mozer P, Cancel-Tassin G, Coté JF, Racoceanu D, Boudghene F, Lucidarme O, Cussenot O, Renard Penna R. Comparison of semi-automated and manual methods to measure the volume of prostate cancer on magnetic resonance imaging. *Diagn Interv Imaging.* 2017 May;98(5):423-428.
91. Léon P, Cancel-Tassin G, Koutlidis N, Calves J, Funes de la Vega M, Fournier G, Valeri A, Cormier L, Larré S, Cussenot O. Prevalence and diversity of management of prostate cancer patients classified as low risk using D'Amico group or Cancer of the Prostate Risk Assessment (CAPRA) score: A French multicenter study. *Prog Urol.* 2017 Mar;27(3):158-165.
92. Cornu JN, Audet-Walsh E, Drouin S, Bigot P, Valeri A, Fournier G, Azzouzi AR, Roupret M, Cormier L, Chanock S, Guillemette C, Cussenot O, Lévesque E, Cancel-Tassin G. Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway. *World J Urol.* 2017 Feb;35(2):293-298.
93. Rozet F, Hennequin C, Beauval JB, Beuzeboc P, Cormier L, Fromont G, Mongiat-Artus P, Ouzzane A, Ploussard G, Azria D, Brenot-Rossi I, Cancel-Tassin G, Cussenot O, Lebreton T, Rebillard X, Soulié M, Renard-Penna R, Méjean A. CCAFU french national guidelines 2016-2018 on prostate cancer. *Prog Urol.* 2016 Nov;27 Suppl 1:S95-S143.
94. Munbahu G, Seisen T, Gomez FD, Peyronnet B, Cussenot O, Shariat SF, Roupret M. Current perspectives of sentinel lymph node dissection at the time of radical surgery for prostate cancer. *Cancer Treat Rev.* 2016 Nov;50:228-239.
95. Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, Musolf A, Li Q, Holzinger E, Karyadi D, Cannon-Albright LA, Teerlink CC, Stanford JL, Isaacs WB, Xu J, Cooney KA, Lange EM, Schleutker J, Carpten JD, Powell IJ, Cussenot O, Cancel-Tassin G, Giles GG, MacInnis RJ, Maier C, Hsieh CL, Wiklund F, Catalona WJ, Foulkes WD, Mandal D, Eeles RA, Kote-Jarai Z, Bustamante CD, Schaid DJ, Hastie T, Ostrander EA, Bailey-Wilson JE, Radivojac P, Thibodeau SN, Whittemore AS, Sieh W. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. *Am J Hum Genet.* 2016 Oct 6;99(4):877-885.
96. Renard Penna R, Cancel-Tassin G, Comperat E, Mozer P, Léon P, Varinot J, Roupret M, Bitker MO, Lucidarme O, Cussenot O. Apparent diffusion coefficient value is a strong predictor of unsuspected aggressiveness of prostate cancer before radical prostatectomy. *World J Urol.* 2016 Oct;34(10):1389-95.
97. Larson NB, McDonnell S, Albright LC, Teerlink C, Stanford J, Ostrander EA, Isaacs WB, Xu J, Cooney KA, Lange E, Schleutker J, Carpten JD, Powell I, Bailey-Wilson J, Cussenot O, Cancel-Tassin G, Giles G, MacInnis R, Maier C, Whittemore AS, Hsieh CL, Wiklund F, Catalona WJ, Foulkes W, Mandal D, Eeles R, Kote-Jarai Z, Ackerman MJ, Olson TM, Klein CJ, Thibodeau SN, Schaid DJ. Post hoc Analysis for Detecting Individual Rare Variant Risk Associations Using Probit Regression Bayesian Variable Selection Methods in Case-Control Sequencing Studies. *Genet Epidemiol.* 2016 Sep;40(6):461-9. Erratum in: *Genet Epidemiol.* 2017 Nov;41(7):710.
98. Teerlink CC, Leongamornlert D, Dadaev T, Thomas A, Farnham J, Stephenson RA, Riska S, McDonnell SK, Schaid DJ, Catalona WJ, Zheng SL, Cooney KA, Ray AM, Zuhlke KA, Lange EM, Giles GG, Southey MC, Fitzgerald LM, Rinckeb A, Luedeke M, Maier C, Stanford JL, Ostrander EA, Kaikkonen EM, Sipeky C, Tammela T, Schleutker J, Wiley KE, Isaacs SD, Walsh PC, Isaacs WB, Xu J, Cancel-Tassin G, Cussenot O, Mandal D, Laurie C, Laurie C; PRACTICAL consortium; International Consortium for Prostate Cancer Genetics, Thibodeau SN, Eeles RA, Kote-Jarai Z, Cannon-Albright L. Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21. *Hum Genet.* 2016 Aug;135(8):923-38.

99. Seisen T, Rouprêt M, Gomez F, Malouf GG, Shariat SF, Peyronnet B, Spano JP, Cancel-Tassin G, Cussenot O. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer. *Cancer Treat Rev.* 2016 Jul;48:25-33.
100. Cornu JN, Cancel-Tassin G, Cox DG, Roupert M, Koutlidis N, Bigot P, Valeri A, Ondet V, Gaffory C, Fournier G, Azzouzi AR, Cormier L, Cussenot O. Impact of Body Mass Index, Age, Prostate Volume, and Genetic Polymorphisms on Prostate-specific Antigen Levels in a Control Population. *Eur Urol.* 2016 Jul;70(1):6-8.
101. Renard-Penna R, Cancel-Tassin G, Comperat E, Varinot J, Léon P, Roupert M, Mozer P, Vaessen C, Lucidarme O, Bitker MO, Cussenot O. Multiparametric Magnetic Resonance Imaging Predicts Postoperative Pathology but Misses Aggressive Prostate Cancers as Assessed by Cell Cycle Progression Score. *J Urol.* 2015 Dec;194(6):1617-23.
102. Cancel-Tassin G, Ondet V, Gaffory C, Orsoni C, Efstathiou T, Cussenot O. Effets pharmacogénomique du Prostaphane® sur des cellules cancéreuses de prostate. *Prog Urol.* 2015 Nov;25(13):837-9.
103. Sampson JN, Wheeler WA, Yeager M, Panagiotou O, Wang Z, Berndt SI, Lan Q, Abnet CC, Amundadottir LT, Figueroa JD, Landi MT, Mirabello L, Savage SA, Taylor PR, De Vivo I, McGlynn KA, Purdue MP, Rajaraman P, Adami HO, Ahlborn A, Albanes D, Amary MF, An SJ, Andersson U, Andriole G Jr, Andrulis IL, Angelucci E, Ansell SM, Arici C, Armstrong BK, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Becker N, Benavente Y, Benhamou S, Berg C, Van Den Berg D, Bernstein L, Bertrand KA, Birmann BM, Black A, Boeing H, Boffetta P, Boutron-Ruault MC, Bracci PM, Brinton L, Brooks-Wilson AR, Bueno-de-Mesquita HB, Burdett L, Buring J, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Carrato A, Carreon T, Carta A, Chan JK, Chang ET, Chang GC, Chang IS, Chang J, Chang-Claude J, Chen CJ, Chen CY, Chen C, Chen CH, Chen C, Chen H, Chen K, Chen KY, Chen KC, Chen Y, Chen YH, Chen YS, Chen YM, Chien LH, Chirlaque MD, Choi JE, Choi YY, Chow WH, Chung CC, Clavel J, Clavel-Chapelon F, Cocco P, Colt JS, Comperat E, Conde L, Connors JM, Conti D, Cortessis VK, Cotterchio M, Cozen W, Crouch S, Crous-Bou M, Cussenot O, Davis FG, Ding T, Diver WR, Dorronsoro M, Dossus L, Duell EJ, Ennas MG, Erickson RL, Feychting M, Flanagan AM, Foretova L, Fraumeni JF Jr, Freedman ND, Beane Freeman LE, Fuchs C, Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, García-Closas R, Gascoyne RD, Gastier-Foster J, Gaudet MM, Gaziano JM, Giffen C, Giles GG, Giovannucci E, Glimelius B, Goggins M, Gokgoz N, Goldstein AM, Gorlick R, Gross M, Grubb R 3rd, Gu J, Guan P, Gunter M, Guo H, Habermann TM, Haiman CA, Halai D, Hallmans G, Hassan M, Hattinger C, He Q, He X, Helzlsouer K, Henderson B, Henriksson R, Hjalgrim H, Hoffman-Bolton J, Hohensee C, Holford TR, Holly EA, Hong YC, Hoover RN, Horn-Ross PL, Hosain GM, Hosgood HD 3rd, Hsiao CF, Hu N, Hu W, Hu Z, Huang MS, Huerta JM, Hung JY, Hutchinson A, Inskip PD, Jackson RD, Jacobs EJ, Jenab M, Jeon HS, Ji BT, Jin G, Jin L, Johansen C, Johnson A, Jung YJ, Kaaks R, Kaminen A, Kane E, Kang CH, Karagas MR, Kelly RS, Khaw KT, Kim C, Kim HN, Kim JH, Kim JS, Kim YH, Kim YT, Kim YC, Kitahara CM, Klein AP, Klein RJ, Kogevinas M, Kohno T, Kolonel LN, Kooperberg C, Krickler A, Krogh V, Kunitoh H, Kurtz RC, Kweon SS, LaCroix A, Lawrence C, Lecanda F, Lee VH, Li D, Li H, Li J, Li YJ, Li Y, Liao LM, Liebow M, Lightfoot T, Lim WY, Lin CC, Lin D, Lindstrom S, Linet MS, Link BK, Liu C, Liu J, Liu L, Ljungberg B, Lloreta J, Di Lollo S, Lu D, Lund E, Malats N, Mannisto S, Le Marchand L, Marina N, Masala G, Mastrangelo G, Matsuo K, Maynadie M, McKay J, McKean-Cowdin R, Melbye M, Melin BS, Michaud DS, Mitsudomi T, Monnereau A, Montalvan R, Moore LE, Mortensen LM, Nieters A, North KE, Novak AJ, Oberg AL, Offit K, Oh JJ, Olson SH, Palli D, Pao W, Park IK, Park JY, Park KH, Patiño-García A, Pavanello S, Peeters PH, Perng RP, Peters U, Petersen GM, Picci P, Pike MC, Porru S, Prescott J, Prokunina-Olsson L, Qian B, Qiao YL, Rais M, Riboli E, Riby J, Risch HA, Rizzato C, Rodabough R, Roman E, Roupert M, Ruder AM, Sanjose Sd, Scelo G, Schned A, Schumacher F, Schwartz K, Schwenn M, Scotlandi K, Seow A, Serra C, Serra M, Sesso HD, Setiawan VW, Severi G, Severson RK, Shanafelt TD, Shen H, Shen W, Shin MH, Shiraishi K, Shu XO, Siddiq A, Sierrasesúmaga L, Sihoe AD, Skibola CF, Smith A, Smith MT, Southey MC, Spinelli JJ, Staines A, Stampfer M, Stern MC, Stevens VL, Stolzenberg-Solomon RS, Su J, Su WC, Sund M, Sung JS, Sung SW, Tan W, Tang W, Tardón A, Thomas D, Thompson CA, Tinker LF, Tirabosco R, Tjønneland A, Travis RC, Trichopoulos D, Tsai FY, Tsai YH, Tucker M, Turner J, Vajdic CM, Vermeulen RC, Villano DJ, Vineis P, Virtamo J, Visvanathan K, Wactawski-Wende J, Wang C, Wang CL, Wang JC, Wang J, Wei F, Weiderpass E, Weiner GJ, Weinstein S, Wentzensen N, White E, Witzig TE, Wolpin BM, Wong MP, Wu C, Wu G, Wu J, Wu T, Wu W, Wu X, Wu YL, Wunder JS, Xiang YB, Xu J, Xu P, Yang PC, Yang TY, Ye Y, Yin Z, Yokota J, Yoon HI, Yu CJ, Yu H, Yu K, Yuan JM, Zelenetz A, Zeleniuch-Jacquotte A, Zhang XC, Zhang Y, Zhao X, Zhao Z, Zheng H, Zheng T, Zheng W, Zhou B, Zhu M, Zucca M, Boca SM, Cerhan JR, Ferri GM, Hartge P, Hsiung CA, Magnani C, Miligi L, Morton LM, Smedby KE, Teras LR, Vijai J, Wang SS, Brennan P, Caporaso NE, Hunter DJ, Kraft P, Rothman N, Silverman DT, Slager SL, Chanock SJ, Chatterjee N. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. *J Natl Cancer Inst.* 2015 Oct 12;107(12):djv279. Erratum in: *J Natl Cancer Inst.* 2016 Apr;108(4). pii: djw106.
104. Cussenot O, Cancel-Tassin G. Precision medicine in oncology needs to integrate pharmacogenetic profiling. *Eur Urol.* 2015 Oct;68(4):630-1.
105. Renard-Penna R, Cancel-Tassin G, Comperat E, Roupert M, Mozer P, Cussenot O. Functional magnetic resonance imaging and molecular pathology at the crossroad of the management of early prostate cancer. *World J Urol.* 2015 Jul;33(7):929-36.

106. Berndt SI, Wang Z, Yeager M, Alavanja MC, Albanes D, Amundadottir L, Andriole G, Beane Freeman L, Campa D, Cancel-Tassin G, Canzian F, Cornu JN, Cussenot O, Diver WR, Gapstur SM, Grönberg H, Haiman CA, Henderson B, Hutchinson A, Hunter DJ, Key TJ, Kolb S, Koutros S, Kraft P, Le Marchand L, Lindström S, Machiela MJ, Ostrander EA, Riboli E, Schumacher F, Siddiq A, Stanford JL, Stevens VL, Travis RC, Tsilidis KK, Virtamo J, Weinstein S, Wilkum F, Xu J, Lilly Zheng S, Yu K, Wheeler W, Zhang H; African Ancestry Prostate Cancer GWAS Consortium, Sampson J, Black A, Jacobs K, Hoover RN, Tucker M, Chanock SJ. Two susceptibility loci identified for prostate cancer aggressiveness. *Nat Commun.* 2015 May 5;6:6889.
107. Helfand BT, Roehl KA, Cooper PR, McGuire BB, Fitzgerald LM, Cancel-Tassin G, Cornu JN, Bauer S, Van Blarigan EL, Chen X, Duggan D, Ostrander EA, Gwo-Shu M, Zhang ZF, Chang SC, Jeong S, Fontham ET, Smith G, Mohler JL, Berndt SI, McDonnell SK, Kittles R, Rybicki BA, Freedman M, Kantoff PW, Pomerantz M, Breyer JP, Smith JR, Rebbeck TR, Mercola D, Isaacs WB, Wiklund F, Cussenot O, Thibodeau SN, Schaid DJ, Cannon-Albright L, Cooney KA, Chanock SJ, Stanford JL, Chan JM, Witte J, Xu J, Bensen JT, Taylor JA, Catalona WJ. Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. *Hum Genet.* 2015 Apr;134(4):439-50.
108. Delage F, Perrouin-Verbe MA, Le Fur E, Papin G, Thoulouzan M, Malhaire JP, Pradier O, Fournier G, Valéri A. Évolution de la fonction érectile après curiethérapie prostatique : étude prospective chez des patients ayant un score IIEF5 initial >16 [Erectile dysfunction evaluation after brachytherapy for low risk prostate adenocarcinoma: prospective study of patients with a baseline IIEF5 >16]. *Prog Urol.* 2015 Feb;25(2):68-74.
109. Cancel-Tassin G, Romana M, Gaffory C, Blanchet P, Cussenot O, Multigner L. Region 2 of 8q24 is associated with the risk of aggressive prostate cancer in Caribbean men of African descent from Guadeloupe (French West Indies). *Asian J Androl.* 2015 Jan-Feb;17(1):117-9.
110. Cussenot O, Cancel-Tassin G. Update on genetic predisposition to prostate cancer. *Bull Cancer.* 2015 Jan;102(1):53-6.
111. Seisen T, Rouprêt M, Brault D, Léon P, Cancel-Tassin G, Compérat E, Renard-Penna R, Mozer P, Guechot J, Cussenot O. Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy. *Prostate.* 2015 Jan;75(1):103-11.
112. Wang Z, Zhu B, Zhang M, Parikh H, Jia J, Chung CC, Sampson JN, Hoskins JW, Hutchinson A, Burdette L, Ibrahim A, Hautman C, Raj PS, Abnet CC, Adjei AA, Ahlborn A, Albanes D, Allen NE, Ambrosone CB, Aldrich M, Amiano P, Amos C, Andersson U, Andriole G Jr, Andrulis IL, Arici C, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Beane Freeman LE, Berg CD, Berndt SI, Bertazzi PA, Biritwum RB, Black A, Blot W, Boeing H, Boffetta P, Bolton K, Boutron-Ruault MC, Bracci PM, Brennan P, Brinton LA, Brotzman M, Bueno-de-Mesquita HB, Buring JE, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Cao G, Caporaso NE, Carrato A, Carreon T, Carta A, Chang GC, Chang IS, Chang-Claude J, Che X, Chen CJ, Chen CY, Chen CH, Chen C, Chen KY, Chen YM, Chokkalingam AP, Chu LW, Clavel-Chapelon F, Colditz GA, Colt JS, Conti D, Cook MB, Cortessis VK, Crawford ED, Cussenot O, Davis FG, De Vivo I, Deng X, Ding T, Dinney CP, Di Stefano AL, Diver WR, Duell EJ, Elena JW, Fan JH, Feigelson HS, Feychting M, Figueroa JD, Flanagan AM, Fraumeni JF Jr, Freedman ND, Fridley BL, Fuchs CS, Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, Garcia-Closas R, Gastier-Foster JM, Gaziano JM, Gerhard DS, Giffen CA, Giles GG, Gillanders EM, Giovannucci EL, Goggins M, Gokgoz N, Goldstein AM, Gonzalez C, Gorlick R, Greene MH, Gross M, Grossman HB, Grubb R 3rd, Gu J, Guan P, Haiman CA, Hallmans G, Hankinson SE, Harris CC, Hartge P, Hattinger C, Hayes RB, He Q, Helman L, Henderson BE, Henriksson R, Hoffman-Bolton J, Hohensee C, Holly EA, Hong YC, Hoover RN, Hosgood HD 3rd, Hsiao CF, Hsing AW, Hsiung CA, Hu N, Hu W, Hu Z, Huang MS, Hunter DJ, Inskip PD, Ito H, Jacobs EJ, Jacobs KB, Jenab M, Ji BT, Johansen C, Johansson M, Johnson A, Kaaks R, Kamat AM, Kamineni A, Karagas M, Khanna C, Khaw KT, Kim C, Kim IS, Kim JH, Kim YH, Kim YC, Kim YT, Kang CH, Jung YJ, Kitahara CM, Klein AP, Klein R, Kogevinas M, Koh WP, Kohno T, Kolonel LN, Kooperberg C, Kratz CP, Krogh V, Kunitoh H, Kurtz RC, Kurucu N, Lan Q, Lathrop M, Lau CC, Lecanda F, Lee KM, Lee MP, Le Marchand L, Lerner SP, Li D, Liao LM, Lim WY, Lin D, Lin J, Lindstrom S, Linet MS, Lissowska J, Liu J, Ljungberg B, Lloreta J, Lu D, Ma J, Malats N, Mannisto S, Marina N, Mastrangelo G, Matsuo K, McGlynn KA, McKean-Cowdin R, McNeill LH, McWilliams RR, Melin BS, Meltzer PS, Mensah JE, Miao X, Michaud DS, Mondul AM, Moore LE, Muir K, Niwa S, Olson SH, Orr N, Panico S, Park JY, Patel AV, Patino-Garcia A, Pavanello S, Peeters PH, Peplonska B, Peters U, Petersen GM, Picci P, Pike MC, Porru S, Prescott J, Pu X, Purdue MP, Qiao YL, Rajaraman P, Riboli E, Risch HA, Rodabough RJ, Rothman N, Ruder AM, Ryu JS, Sanson M, Schned A, Schumacher FR, Schwartz AG, Schwartz KL, Schwenn M, Scotlandi K, Seow A, Serra C, Serra M, Sesso HD, Severi G, Shen H, Shen M, Shete S, Shiraishi K, Shu XO, Siddiq A, Sierrasesumaga L, Sierri S, Loon Sihoe AD, Silverman DT, Simon M, Southey MC, Spector L, Spitz M, Stampfer M, Stattin P, Stern MC, Stevens VL, Stolzenberg-Solomon RZ, Stram DO, Strom SS, Su WC, Sund M, Sung SW, Swerdlow A, Tan W, Tanaka H, Tang W, Tang ZZ, Tardon A, Tay E, Taylor PR, Tetley Y, Thomas DM, Tirabosco R, Tjonneland A, Tobias GS, Toro JR, Travis RC, Trichopoulos D, Troisi R, Truelove A, Tsai YH, Tucker MA, Tumino R, Van Den Berg D, Van Den Eeden SK, Vermeulen R, Vineis P, Visvanathan K, Vogel U, Wang C, Wang C, Wang J, Wang SS, Weiderpass E, Weinstein SJ, Wentzensen N, Wheeler W, White E, Wiencke JK, Wolk A, Wolpin BM, Wong MP, Wrensch M, Wu C, Wu T, Wu X, Wu YL, Wunder JS, Xiang YB, Xu J, Yang HP, Yang PC, Yatabe Y, Ye Y, Yeboah ED, Yin Z, Ying C, Yu CJ, Yu K, Yuan JM, Zanetti KA, Zeleniuch-Jacquotte A, Zheng W, Zhou B, Mirabello L, Savage SA, Kraft P, Chanock

- SJ, Yeager M, Landi MT, Shi J, Chatterjee N, Amundadottir LT. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. *Hum Mol Genet.* 2014 Dec 15;23(24):6616-33.
113. Debiais-Delpech C, Godet J, Pedretti N, Bernard FX, Irani J, Cathelineau X, Cussenot O, Fromont G. Expression patterns of candidate susceptibility genes HNF1 β and CtBP2 in prostate cancer: association with tumor progression. *Urol Oncol.* 2014 May;32(4):426-32.
114. Teerlink CC, Thibodeau SN, McDonnell SK, Schaid DJ, Rinckleb A, Maier C, Vogel W, Cancel-Tassin G, Egrot C, Cussenot O, Foulkes WD, Giles GG, Hopper JL, Severi G, Eeles R, Easton D, Kote-Jarai Z, Guy M, Cooney KA, Ray AM, Zuhlke KA, Lange EM, Fitzgerald LM, Stanford JL, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Isaacs WB, Wahlfors T, Tammela T, Schleutker J, Wiklund F, Grönberg H, Emanuelsson M, Carpten J, Bailey-Wilson J, Whittemore AS, Oakley-Girvan I, Hsieh CL, Catalona WJ, Zheng SL, Jin G, Lu L, Xu J; International Consortium for Prostate Cancer Genetics, Camp NJ, Cannon-Albright LA. Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. *Hum Genet.* 2014 Mar;133(3):347-56.
115. Fromont G, Godet J, Peyret A, Irani J, Celhay O, Rozet F, Cathelineau X, Cussenot O. 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy. *Hum Pathol.* 2013 Aug;44(8):1617-23.
116. Eisinger F, Cancel-Tassin G, Azzouzi AR, Gravis G, Rossi D, Cussenot O. Pharmacologic and diet based prostate cancer prevention. *Bull Cancer.* 2013 May;100(5):497-507.
117. Bigot P, Mouzat K, Lebdaï S, Bahut M, Benhabiles N, Tassin GC, Azzouzi AR, Cussenot O. Quantitative proteomic determination of diethylstilbestrol action on prostate cancer. *Asian J Androl.* 2013 May;15(3):413-20.
118. Cornu JN, Cancel-Tassin G, Egrot C, Gaffory C, Haab F, Cussenot O. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer. *Prostate.* 2013 Feb 15;73(3):242-9.
119. Xu J, Lange EM, Lu L, Zheng SL, Wang Z, Thibodeau SN, Cannon-Albright LA, Teerlink CC, Camp NJ, Johnson AM, Zuhlke KA, Stanford JL, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Maier C, Luedeke M, Vogel W, Schleutker J, Wahlfors T, Tammela T, Schaid D, McDonnell SK, DeRycke MS, Cancel-Tassin G, Cussenot O, Wiklund F, Grönberg H, Eeles R, Easton D, Kote-Jarai Z, Whittemore AS, Hsieh CL, Giles GG, Hopper JL, Severi G, Catalona WJ, Mandal D, Ledet E, Foulkes WD, Hamel N, Mahle L, Møller P, Powell I, Bailey-Wilson JE, Carpten JD, Seminara D, Cooney KA, Isaacs WB; International Consortium for Prostate Cancer Genetics. HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). *Hum Genet.* 2013 Jan;132(1):5-14.
120. Yates DR, Rouprêt M, Drouin SJ, Comperat E, Ricci S, Lacave R, Sèbe P, Cancel-Tassin G, Bitker MO, Cussenot O. Quantitative RT-PCR analysis of PSA and prostate-specific membrane antigen mRNA to detect circulating tumor cells improves recurrence-free survival nomogram prediction after radical prostatectomy. *Prostate.* 2012 Sep 1;72(12):1382-8.
121. Fromont G, Rozet F, Cathelineau X, Ouzzane A, Doucet L, Fournier G, Cussenot O. BCAR1 expression improves prediction of biochemical recurrence after radical prostatectomy. *Prostate.* 2012 Sep 1;72(12):1359-65.
122. Drouin SJ, Comperat E, Cussenot O, Bitker MO, Haertig A, Rouprêt M. Clinical characteristics and pathologic findings in patients eligible for active surveillance who underwent radical prostatectomy. *Urol Oncol.* 2012 Jul-Aug;30(4):402-7.
123. Wang Z, Parikh H, Jia J, Myers T, Yeager M, Jacobs KB, Hutchinson A, Burdett L, Ghosh A, Thun MJ, Gapstur SM, Ryan Diver W, Virtamo J, Albanes D, Cancel-Tassin G, Valeri A, Cussenot O, Offit K, Giovannucci E, Ma J, Stampfer MJ, Michael Gaziano J, Hunter DJ, Dutra-Clarke A, Kirchhoff T, Alavanja M, Freeman LB, Koutros S, Hoover R, Berndt SI, Hayes RB, Agalliu I, Burk RD, Wacholder S, Thomas G, Amundadottir L. Y chromosome haplogroups and prostate cancer in populations of European and Ashkenazi Jewish ancestry. *Hum Genet.* 2012 Jul;131(7):1173-85.
124. Jin G, Lu L, Cooney KA, Ray AM, Zuhlke KA, Lange EM, Cannon-Albright LA, Camp NJ, Teerlink CC, Fitzgerald LM, Stanford JL, Wiley KE, Isaacs SD, Walsh PC, Foulkes WD, Giles GG, Hopper JL, Severi G, Eeles R, Easton D, Kote-Jarai Z, Guy M, Rinckleb A, Maier C, Vogel W, Cancel-Tassin G, Egrot C, Cussenot O, Thibodeau SN, McDonnell SK, Schaid DJ, Wiklund F, Grönberg H, Emanuelsson M, Whittemore AS, Oakley-Girvan I, Hsieh CL, Wahlfors T, Tammela T, Schleutker J, Catalona WJ, Zheng SL, Ostrander EA, Isaacs WB, Xu J; International Consortium for Prostate Cancer Genetics. Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG). *Hum Genet.* 2012 Jul;131(7):1095-103.
125. Bailey-Wilson JE, Childs EJ, Cropp CD, Schaid DJ, Xu J, Camp NJ, Cannon-Albright LA, Farnham JM, George A, Powell I, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, Foulkes WD, Mæhle L, Møller P, Eeles R, Easton D, Guy M, Edwards S, Badzioch MD, Whittemore AS, Oakley-Girvan I, Hsieh CL, Dimitrov L, Stanford JL, Karyadi DM, Deutsch K, McIntosh L, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Thibodeau SN, McDonnell SK, Hebringer S, Lange EM, Cooney KA, Tammela TL, Schleutker J, Maier C, Bochum S, Hoegel J, Grönberg H, Wiklund F, Emanuelsson M, Cancel-Tassin G, Valeri A, Cussenot O, Isaacs WB;

- International Consortium for Prostate Cancer Genetics. Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families. *BMC Med Genet*. 2012 Jun 19;13:46.
126. Larré S, Camparo P, Comperat E, Boulbés D, Haddoum M, Baulande S, Soularue P, Costa P, Cussenot O. Biological effect of human serum collected before and after oral intake of *Pygeum africanum* on various benign prostate cell cultures. *Asian J Androl*. 2012 May;14(3):499-504.
127. Audenet F, Seringe E, Drouin SJ, Comperat E, Cussenot O, Bitker MO, Rouprêt M. Persistently elevated prostatespecific antigen at six weeks after radical prostatectomy helps in early identification of patients who are likely to recur. *World J Urol*. 2012 Apr;30(2):239-44.
128. Lu L, Cancel-Tassin G, Valeri A, Cussenot O, Lange EM, Cooney KA, Farnham JM, Camp NJ, Cannon-Albright LA, Tammela TL, Schleutker J, Hoegel J, Herkommer K, Maier C, Vogel W, Wiklund F, Emanuelsson M, Grönberg H, Wiley KE, Isaacs SD, Walsh PC, Helfand BT, Kan D, Catalona WJ, Stanford JL, FitzGerald LM, Johanneson B, Deutsch K, McIntosh L, Ostrander EA, Thibodeau SN, McDonnell SK, Hebring S, Schaid DJ, Whittemore AS, Oakley-Girvan I, Hsieh CL, Powell I, Bailey-Wilson JE, Cropp CD, Simpson C, Carpten JD, Seminara D, Zheng SL, Xu J, Giles GG, Severi G, Hopper JL, English DR, Foulkes WD, Maehle L, Moller P, Badzioch MD, Edwards S, Guy M, Eeles R, Easton D, Isaacs WB; International Consortium for Prostate Cancer Genetics. Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG. *Prostate*. 2012 Mar;72(4):410-26.
129. Giton F, Fiet J, Cornu JN, Cussenot O, Bélanger A, Urien S, Oliva A, Blanchet P, Multigner L. Serum sex steroids measured in middle-aged European and African-Caribbean men by gas chromatography-mass spectrometry. *Eur J Endocrinol*. 2011 Dec;165(6):917-24.
130. Audenet F, Comperat E, Seringe E, Drouin SJ, Richard F, Cussenot O, Bitker MO, Rouprêt M. Oncologic control obtained after radical prostatectomy in men with a pathological Gleason score ≥ 8 : a single-center experience. *Urol Oncol*. 2011 Nov-Dec;29(6):602-7.
131. Ciampa J, Yeager M, Jacobs K, Thun MJ, Gapstur S, Albanes D, Virtamo J, Weinstein SJ, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Hunter D, Hoover R, Thomas G, Chanock S, Holmes C, Chatterjee N. Application of a novel score test for genetic association incorporating gene-gene interaction suggests functionality for prostate cancer susceptibility regions. *Hum Hered*. 2011;72(3):182-93.
132. Masson-Lecomte A, Hupertan V, Comperat E, Vaessen C, Chartier-Kastler E, Cussenot O, Bitker MO, Rouprêt M. Pathological findings and oncological control afforded by radical prostatectomy in men with high-risk prostate cancer: a single-centre study. *World J Urol*. 2011 Oct;29(5):665-70.
133. Berndt SI, Sampson J, Yeager M, Jacobs KB, Wang Z, Hutchinson A, Chung C, Orr N, Wacholder S, Chatterjee N, Yu K, Kraft P, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Haiman C, Henderson B, Kolonel L, Le Marchand L, Siddiq A, Riboli E, Travis RC, Kaaks R, Isaacs W, Isaacs S, Wiley KE, Gronberg H, Wiklund F, Stattin P, Xu J, Zheng SL, Sun J, Vatten LJ, Hveem K, Njølstad I, Gerhard DS, Tucker M, Hayes RB, Hoover RN, Fraumeni JF Jr, Hunter DJ, Thomas G, Chanock SJ. Large-scale fine mapping of the HNF1B locus and prostate cancer risk. *Hum Mol Genet*. 2011 Aug 15;20(16):3322-9.
134. Chung CC, Ciampa J, Yeager M, Jacobs KB, Berndt SI, Hayes RB, Gonzalez-Bosquet J, Kraft P, Wacholder S, Orr N, Yu K, Hutchinson A, Boland J, Chen Q, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Haiman CA, Henderson BE, Kolonel L, Le Marchand L, Siddiq A, Riboli E, Key TJ, Kaaks R, Isaacs WB, Isaacs SD, Grönberg H, Wiklund F, Xu J, Vatten LJ, Hveem K, Njølstad I, Gerhard DS, Tucker M, Hoover RN, Fraumeni JF Jr, Hunter DJ, Thomas G, Chatterjee N, Chanock SJ. Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer. *Hum Mol Genet*. 2011 Jul 15;20(14):2869-78.
135. Parikh H, Wang Z, Pettigrew KA, Jia J, Daugherty S, Yeager M, Jacobs KB, Hutchinson A, Burdett L, Cullen M, Qi L, Boland J, Collins I, Albert TJ, Vatten LJ, Hveem K, Njølstad I, Cancel-Tassin G, Cussenot O, Valeri A, Virtamo J, Thun MJ, Feigelson HS, Diver WR, Chatterjee N, Thomas G, Albanes D, Chanock SJ, Hunter DJ, Hoover R, Hayes RB, Berndt SI, Sampson J, Amundadottir L. Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels. *Hum Genet*. 2011 Jun;129(6):675-85.
136. Cornu JN, Drouin S, Cancel-Tassin G, Bigot P, Azzouzi AR, Koutlidis N, Cormier L, Gaffory C, Rouprêt M, Sèbe P, Bitker MO, Haab F, Cussenot O. Impact of genotyping on outcome of prostatic biopsies: a multicenter prospective study. *Mol Med*. 2011 May-Jun;17(5-6):473-7.
137. Ciampa J, Yeager M, Amundadottir L, Jacobs K, Kraft P, Chung C, Wacholder S, Yu K, Wheeler W, Thun MJ, Divers WR, Gapstur S, Albanes D, Virtamo J, Weinstein S, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Hunter D, Hoover R, Thomas G, Chanock S, Chatterjee N. Large-scale exploration of gene-gene interactions in prostate cancer using a multistage genomewide association study. *Cancer Res*. 2011 May 1;71(9):3287-95.

138. Cussenot O, Comperat E, Bitker MO, Rouprêt M. From active surveillance to the concept of secondary prevention. *Eur Urol.* 2011 Apr;59(4):568-71.
139. Fromont G, Cussenot O. The integrin signalling adaptor p130CAS is also a key player in prostate cancer. *Nat Rev Cancer.* 2011 Mar;11(3):227.
140. Cornu JN, Cancel-Tassin G, Ondet V, Girardet C, Cussenot O. Olfactory detection of prostate cancer by dogs sniffing urine: a step forward in early diagnosis. *Eur Urol.* 2011 Feb;59(2):197-201.
141. Bitker MO, Roupret M, Cussenot O. Toward a new border. *Prog Urol.* 2011 Feb;21(2):154-5.
142. Valeri A, Malavaud B, Desrichard O, Cornu JN, Blanchet P, Dervaux B, Puech P, Villers A, Cancel-Tassin G, Cussenot O. Strategies for early diagnosis and prevention of prostate cancer. *Bull Cancer.* 2010 Dec;97(12):1499-515.
143. Celhay O, Yacoub M, Irani J, Dore B, Cussenot O, Fromont G. Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression. *J Urol.* 2010 Nov;184(5):2172-8.
144. Compérat E, Rouprêt M, Drouin SJ, Camparo P, Bitker MO, Houlgatte A, Cancel-Tassin G, Cussenot O. Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy. *Prostate.* 2010 Nov 1;70(15):1622-7.
145. Prokunina-Olsson L, Fu YP, Tang W, Jacobs KB, Hayes RB, Kraft P, Berndt SI, Wacholder S, Yu K, Hutchinson A, Spencer Feigelson H, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Haiman CA, Henderson BE, Kolonel L, Le Marchand L, Siddiq A, Riboli E, Travis R, Kaaks R, Isaacs WB, Isaacs SD, Grönberg H, Wiklund F, Xu J, Vatten LJ, Hveem K, Kumle M, Tucker M, Hoover RN, Fraumeni JF Jr, Hunter DJ, Thomas G, Chatterjee N, Chanock SJ, Yeager M. Refining the prostate cancer genetic association within the JAZF1 gene on chromosome 7p15.2. *Cancer Epidemiol Biomarkers Prev.* 2010 May;19(5):1349-55.
146. Phé V, Cussenot O, Rouprêt M. Methylated genes as potential biomarkers in prostate cancer. *BJU Int.* 2010 May;105(10):1364-70.
147. Yacoub M, Coulon A, Celhay O, Irani J, Cussenot O, Fromont G. Differential expression of the semaphorin 3A pathway in prostatic cancer. *Histopathology.* 2009 Oct;55(4):392-8.
148. Yeager M, Chatterjee N, Ciampa J, Jacobs KB, Gonzalez-Bosquet J, Hayes RB, Kraft P, Wacholder S, Orr N, Berndt S, Yu K, Hutchinson A, Wang Z, Amundadottir L, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Haiman CA, Henderson B, Kolonel L, Le Marchand L, Siddiq A, Riboli E, Key TJ, Kaaks R, Isaacs W, Isaacs S, Wiley KE, Gronberg H, Wiklund F, Stattin P, Xu J, Zheng SL, Sun J, Vatten LJ, Hveem K, Kumle M, Tucker M, Gerhard DS, Hoover RN, Fraumeni JF Jr, Hunter DJ, Thomas G, Chanock SJ. Identification of a new prostate cancer susceptibility locus on chromosome 8q24. *Nat Genet.* 2009 Oct;41(10):1055-7.
149. Nguyen K, Eltz S, Drouin SJ, Comperat E, Audenet F, Renard-Penna R, Bitker MO, Chartier-Kastler E, Richard F, Cussenot O, Rouprêt M. Oncologic outcome after radical prostatectomy in men with PSA values above 20 ng/ml: a monocentric experience. *World J Urol.* 2009 Oct;27(5):653-8.
150. Rouprêt M, Hupertan V, Comperat E, Drouin SJ, Phé V, Xylinas E, Demanse D, Sibony M, Richard F, Cussenot O. Cross-cultural validation of a prognostic tool: example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy. *BJU Int.* 2009 Sep;104(6):813-7; discussion 817-8.
151. Lou H, Yeager M, Li H, Bosquet JG, Hayes RB, Orr N, Yu K, Hutchinson A, Jacobs KB, Kraft P, Wacholder S, Chatterjee N, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Ma J, Gaziano JM, Stampfer M, Schumacher FR, Giovannucci E, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Anderson SK, Tucker M, Hoover RN, Fraumeni JF Jr, Thomas G, Hunter DJ, Dean M, Chanock SJ. Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. *Proc Natl Acad Sci U S A.* 2009 May 12;106(19):7933-8.
152. Nicolaiew N, Cancel-Tassin G, Azzouzi AR, Grand BL, Mangin P, Cormier L, Fournier G, Giordanella JP, Pouchard M, Escary JL, Valeri A, Cussenot O. Association between estrogen and androgen receptor genes and prostate cancer risk. *Eur J Endocrinol.* 2009 Jan;160(1):101-6.
153. Larré S, Tran N, Fan C, Hamadeh H, Champigneulle J, Azzouzi R, Cussenot O, Mangin P, Olivier JL. PGE2 and LTB4 tissue levels in benign and cancerous prostates. *Prostaglandins Other Lipid Mediat.* 2008 Dec;87(1-4):14-9.
154. Ahn J, Berndt SI, Wacholder S, Kraft P, Kibel AS, Yeager M, Albanes D, Giovannucci E, Stampfer MJ, Virtamo J, Thun MJ, Feigelson HS, Cancel-Tassin G, Cussenot O, Thomas G, Hunter DJ, Fraumeni JF Jr, Hoover RN, Chanock SJ, Hayes RB. Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. *Nat Genet.* 2008 Sep;40(9):1032-4; author reply 1035-6.
155. Cussenot O, Azzouzi AR, Bantsimba-Malanda G, Gaffory C, Mangin P, Cormier L, Fournier G, Valeri A, Jouffe L, Roupret M, Fromont G, Sibony M, Comperat E, Cancel-Tassin G. Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer. *Clin Cancer Res.* 2008 Sep 1;14(17):5635-9.

156. Fromont G, Yacoub M, Valeri A, Mangin P, Vallancien G, Cancel-Tassin G, Cussenot O. Differential expression of genes related to androgen and estrogen metabolism in hereditary versus sporadic prostate cancer. *Cancer Epidemiol Biomarkers Prev*. 2008 Jun;17(6):1505-9.
157. Hamadeh H, Larré S, Azzouzi AR, Cancel-Tassin G, Vallancien G, Cochand-Priollet B, Cussenot O. Facteurs génétiques déterminant les variations anatomiques de la prostate [Genetic determinants of anatomical variants of the prostate]. *Prog Urol*. 2008 Apr;18(4):214-22.
158. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Deng X, Berndt SI, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hayes RB, Hunter DJ, Chanock SJ. Multiple loci identified in a genome-wide association study of prostate cancer. *Nat Genet*. 2008 Mar;40(3):310-5.
159. Cussenot O, Azzouzi AR, Nicolaiew N, Mangin P, Cormier L, Fournier G, Valeri A, Cancel-Tassin G. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. *Eur Urol*. 2007 Oct;52(4):1082-7.
160. Larre S, Azzouzi AR, Cormier L, Cancel-Tassin G, Drelon I, Baschet F, Villette JM, Cussenot O, Mangin P. How is prostate cancer screening perceived by men 50 to 70 years of age? Analysis based on 1,774 screened individuals. *Prog Urol*. 2007 Sep;17(5):939-42.
161. Cussenot O, Azzouzi AR, Nicolaiew N, Fromont G, Mangin P, Cormier L, Fournier G, Valeri A, Larre S, Thibault F, Giordanella JP, Pouchard M, Zheng Y, Hamdy FC, Cox A, Cancel-Tassin G. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. *J Clin Oncol*. 2007 Aug 20;25(24):3596-602.
162. Larré S, Azzouzi AR, Cancel-Tassin G, Cormier L, Villette JM, Hoffmann P, Drelon I, Baschet F, Mangin P, Cussenot O. Impact of obesity on PSA in prostate cancer screening. *Prog Urol*. 2007 Jun;17(4):815-8.
163. Azzouzi AR, Stoppa-Lyonnet D, Roupert M, Larre S, Mangin P, Cussenot O. BRCA2 mutation screening is clinically relevant in breast and early prostate cancer families. *Int J Urol*. 2007 May;14(5):445-6.
164. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hunter DJ, Chanock SJ, Thomas G. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. *Nat Genet*. 2007 May;39(5):645-9.
165. Azzouzi AR, Catto JW, Rehman I, Larre S, Roupert M, Feeley KM, Cussenot O, Meuth M, Hamdy FC. Clinically localised prostate cancer is microsatellite stable. *BJU Int*. 2007 May;99(5):1031-5.
166. Azzouzi AR, Larre S, Cormier L, Roupert M, Valeri A, Mangin P, Berthon P, Villette JM, Fiet J, Cussenot O. Relevance of the prostate-specific antigen (PSA) nanotest compared to the classical PSA test in the organized mass screening of prostate cancer. *BJU Int*. 2007 Apr;99(4):762-4.
167. Roupert M, Hupertan V, Yates DR, Catto JW, Rehman I, Meuth M, Ricci S, Lacave R, Cancel-Tassin G, de la Taille A, Rozet F, Cathelineau X, Vallancien G, Hamdy FC, Cussenot O. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. *Clin Cancer Res*. 2007 Mar 15;13(6):1720-5.
168. Fromont G, Vallancien G, Validire P, Levillain P, Cussenot O. BCAR1 expression in prostate cancer: association with 16q23 LOH status, tumor progression and EGFR/KAI1 staining. *Prostate*. 2007 Feb 15;67(3):268-73.
169. Roupert M, Fromont G, Bitker MO, Gattegno B, Vallancien G, Cussenot O. Outcome after radical prostatectomy in young men with or without a family history of prostate cancer. *Urology*. 2006 May;67(5):1028-32.
170. Cancel-Tassin G, Cussenot O. Genetic susceptibility to prostate cancer. *BJU Int*. 2005 Dec;96(9):1380-5.
171. Cancel-Tassin G, Cussenot O. Prostate cancer genetics. *Minerva Urol Nefrol*. 2005 Dec;57(4):289-300.
172. Fromont G, Valeri A, Cher M, Pontes JE, Vallancien G, Validire P, Latil A, Cussenot O. Allelic loss at 16q23.2 is associated with good prognosis in high grade prostate cancer. *Prostate*. 2005 Dec 1;65(4):341-6.
173. Valeri A, Fromont G, Sakr W, Azzouzi R, Dey J, Chantrel-Groussard K, Latil A, Berthon P, Cussenot O, Pontes JE, Cher ML. High frequency of allelic losses in high-grade prostate cancer is associated with biochemical progression after radical prostatectomy. *Urol Oncol*. 2005 Mar-Apr;23(2):87-92.
174. Fromont G, Chene L, Vidaud M, Vallancien G, Mangin P, Fournier G, Validire P, Latil A, Cussenot O. Differential expression of 37 selected genes in hormone-refractory prostate cancer using quantitative taqman real-time RTPCR. *Int J Cancer*. 2005 Mar 20;114(2):174-81.
175. Thuret R, Chantrel-Groussard K, Azzouzi AR, Villette JM, Guimard S, Teillac P, Berthon P, Houlgatte A, Latil A, Cussenot O. Clinical relevance of genetic instability in prostatic cells obtained by prostatic massage in early prostate cancer. *Br J Cancer*. 2005 Jan 31;92(2):236-40.

176. Fromont G, Chene L, Latil A, Bieche I, Vidaud M, Vallancien G, Mangin P, Fournier G, Validire P, Cussenot O. Molecular profiling of benign prostatic hyperplasia using a large scale real-time reverse transcriptase-polymerase chain reaction approach. *J Urol*. 2004 Oct;172(4 Pt 1):1382-5.
177. Algarte-Génin M, Cussenot O, Costa P. Prevention of prostate cancer by androgens: experimental paradox or clinical reality. *Eur Urol*. 2004 Sep;46(3):285-94; discussion 294-5.
178. Chêne L, Giroud C, Desgrandchamps F, Boccon-Gibod L, Cussenot O, Berthon P, Latil A. Extensive analysis of the 7q31 region in human prostate tumors supports TES as the best candidate tumor suppressor gene. *Int J Cancer*. 2004 Sep 20;111(5):798-804.
179. Rehman I, Cross SS, Azzouzi AR, Catto JW, Deloulme JC, Larre S, Champigneulle J, Fromont G, Cussenot O, Hamdy FC. S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors. *Br J Cancer*. 2004 Aug 16;91(4):739-44.
180. Cussenot O, Cancel-Tassin G. Genetic susceptibility to prostate cancer. *Med Sci (Paris)*. 2004 May;20(5):562-8.
181. Latil A, Bièche I, Chêne L, Laurendeau I, Berthon P, Cussenot O, Vidaud M. Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior. *Clin Cancer Res*. 2003 Nov 15;9(15):5477-85.
182. Fromont G, Joulin V, Chantrel-Groussard K, Vallancien G, Guillonnet B, Validire P, Latil A, Cussenot O. Allelic losses in localized prostate cancer: association with prognostic factors. *J Urol*. 2003 Oct;170(4 Pt 1):1394-7.
183. Cancel-Tassin G, Latil A, Rousseau F, Mangin P, Bottius E, Escary JL, Berthon P, Cussenot O. Association study of polymorphisms in the human estrogen receptor alpha gene and prostate cancer risk. *Eur Urol*. 2003 Oct;44(4):487-90.
184. Latil A, Chêne L, Mangin P, Fournier G, Berthon P, Cussenot O. Extensive analysis of the 13q14 region in human prostate tumors: DNA analysis and quantitative expression of genes lying in the interval of deletion. *Prostate*. 2003 Sep 15;57(1):39-50.
185. Azzouzi AR, Valeri A, Cormier L, Fournier G, Mangin P, Cussenot O. Familial prostate cancer cases before and after radical prostatectomy do not show any aggressiveness compared with sporadic cases. *Urology*. 2003 Jun;61(6):1193-7.
186. Valeri A, Briollais L, Azzouzi R, Fournier G, Mangin P, Berthon P, Cussenot O, Demeais F. Segregation analysis of prostate cancer in France: evidence for autosomal dominant inheritance and residual brother-brother dependence. *Ann Hum Genet*. 2003 Mar;67(Pt 2):125-37.
187. Latil A, Chêne L, Cochant-Priollet B, Mangin P, Fournier G, Berthon P, Cussenot O. Quantification of expression of netrins, slits and their receptors in human prostate tumors. *Int J Cancer*. 2003 Jan 20;103(3):306-15.
188. Azzouzi AR, Cochand-Priollet B, Mangin P, Fournier G, Berthon P, Latil A, Cussenot O. Impact of constitutional genetic variation in androgen/oestrogen-regulating genes on age-related changes in human prostate. *Eur J Endocrinol*. 2002 Oct;147(4):479-84.
189. Maier C, Rösch K, Herkommer K, Bochum S, Cancel-Tassin G, Cussenot O, Häussler J, Assum G, Vogel W, Paiss T. A candidate gene approach within the susceptibility region PCaP on 1q42.2-43 excludes deleterious mutations of the PCTA-1 gene to be responsible for hereditary prostate cancer. *Eur Urol*. 2002 Sep;42(3):301-7.
190. Valeri A, Cormier L, Moineau MP, Cancel-Tassin G, Azzouzi R, Doucet L, Baschet F, Cussenot O, L'Her J, Berthon P, Mangin P, Cussenot O, Morin JF, Fournier G. Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives. *J Urol*. 2002 Aug;168(2):483-7.
191. Naimi B, Latil A, Fournier G, Mangin P, Cussenot O, Berthon P. Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. *Prostate*. 2002 Aug 1;52(3):245-52.
192. Cormier L, Guillemain F, Valéri A, Fournier G, Cussenot O, Mangin P, Litwin MS. Impact of prostate cancer screening on health-related quality of life in at-risk families. *Urology*. 2002 Jun;59(6):901-6.
193. Latil A, Morant P, Fournier G, Mangin P, Berthon P, Cussenot O. CHC1-L, a candidate gene for prostate carcinogenesis at 13q14.2, is frequently affected by loss of heterozygosity and underexpressed in human prostate cancer. *Int J Cancer*. 2002 Jun 10;99(5):689-96.
194. Cormier L, Valéri A, Azzouzi R, Fournier G, Cussenot O, Berthon P, Guillemain F, Mangin P. Worry and attitude of men in at-risk families for prostate cancer about genetic susceptibility and genetic testing. *Prostate*. 2002 Jun 1;51(4):276-85.
195. Bièche I, Latil A, Parfait B, Vidaud D, Laurendeau I, Lidereau R, Cussenot O, Vidaud M. CGA gene (coding for the alpha subunit of glycoprotein hormones) overexpression in ER alpha-positive prostate tumors. *Eur Urol*. 2002 Mar;41(3):335-41.
196. Latil AG, Azzouzi R, Cancel GS, Guillaume EC, Cochand-Priollet B, Berthon PL, Cussenot O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. *Cancer*. 2001 Sep 1;92(5):1130-7.
197. Cancel-Tassin G, Latil A, Valéri A, Guillaume E, Mangin P, Fournier G, Berthon P, Cussenot O. No evidence of linkage to HPC20 on chromosome 20q13 in hereditary prostate cancer. *Int J Cancer*. 2001 Aug 1;93(3):455-6.

198. Latil A, Guérard M, Berthon P, Cussenot O. 12p12-13 deletion in prostate tumors and quantitative expression of CDKN1B and ETV6 candidate genes. *Genes Chromosomes Cancer*. 2001 Jun;31(2):199-200.
199. Latil A, Bièche I, Vidaud D, Lidereau R, Berthon P, Cussenot O, Vidaud M. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. *Cancer Res*. 2001 Mar 1;61(5):1919-26.
200. Cancel-Tassin G, Latil A, Valéri A, Mangin P, Fournier G, Berthon P, Cussenot O. PCAP is the major known prostate cancer predisposing locus in families from south and west Europe. *Eur J Hum Genet*. 2001 Feb;9(2):135-42.
201. Cussenot O, Teillac P, Berthon P, Latil A. Noninvasive detection of genetic instability in cells from prostatic secretion as a marker of prostate cancer. *Eur J Intern Med*. 2001 Feb;12(1):17-19.
202. Cussenot O, Valeri A. Heterogeneity in genetic susceptibility to prostate cancer. *Eur J Intern Med*. 2001 Feb;12(1):11-16.
203. Anidjar M, Villette JM, Devauchelle P, Delisle F, Cotard JP, Billotey C, Cochand-Priollet B, Copin H, Barnoux M, Triballeau S, Rain JD, Fiet J, Teillac P, Berthon P, Cussenot O. In vivo model mimicking natural history of dog prostate cancer using DPC-1, a new canine prostate carcinoma cell line. *Prostate*. 2001 Jan 1;46(1):2-10.
204. Valeri A, Azzouzi R, Drelon E, Delannoy A, Mangin P, Fournier G, Berthon P, Cussenot O. Early-onset hereditary prostate cancer is not associated with specific clinical and biological features. *Prostate*. 2000 Sep 15;45(1):66-71.
205. Naimi B, Latil A, Berthon P, Cussenot O. No evidence for fibroblast growth factor receptor 3 (FGFR-3) R248C/S249C mutations in human prostate cancer. *Int J Cancer*. 2000 Aug 1;87(3):455-6.
206. Valeri A, Fournier G, Morin V, Morin JF, Drelon E, Mangin P, Teillac P, Berthon P, Cussenot O. Early onset and familial predisposition to prostate cancer significantly enhance the probability for breast cancer in first degree relatives. *Int J Cancer*. 2000 Jun 15;86(6):883-7.
207. Correa-Cerro L, Berthon P, Häussler J, Bochum S, Drelon E, Mangin P, Fournier G, Paiss T, Cussenot O, Vogel W. Vitamin D receptor polymorphisms as markers in prostate cancer. *Hum Genet*. 1999 Sep;105(3):281-7.
208. Valeri A, Drelon E, Paiss T, Vogel W, de Petriconi R, Hautmann R, Fournier G, Mangin P, Berthon P, Cussenot O. Genetic analysis of familial prostatic cancer: localization of a gene predisposing to prostatic cancer (PCaP) on chromosome 1q 42.2-43. *Prog Urol*. 1999 Sep;9(4):680-8.
209. Valeri A, Drelon E, Azzouzi R, Delannoy A, Teillac P, Fournier G, Mangin P, Berthon P, Cussenot O. Epidemiology of familial prostatic cancer: 4-year assessment of French studies. *Prog Urol*. 1999 Sep;9(4):672-9.
210. Ropiquet F, Huguenin S, Villette JM, Ronflé V, Le Brun G, Maitland NJ, Cussenot O, Fiet J, Berthon P. FGF7/KGF triggers cell transformation and invasion on immortalised human prostatic epithelial PNT1A cells. *Int J Cancer*. 1999 Jul 19;82(2):237-43.
211. Correa-Cerro L, Wöhr G, Häussler J, Berthon P, Drelon E, Mangin P, Fournier G, Cussenot O, Kraus P, Just W, Paiss T, Cantú JM, Vogel W. (CAG)_nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population. *Eur J Hum Genet*. 1999 Apr;7(3):357-62.
212. Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wöhr G, Latil A, Millasseau P, Mellah I, Cohen N, Blanché H, Bellané-Chantelot C, Demenais F, Teillac P, Le Duc A, de Petriconi R, Hautmann R, Chumakov I, Bachner L, Maitland NJ, Lidereau R, Vogel W, Fournier G, Mangin P, Cussenot O. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. *Am J Hum Genet*. 1998 Jun;62(6):1416-24.
213. Valeri A, Berthon P, Fournier G, Buzzi JC, Briollais L, Meria P, Blanche H, Bellané-Chantelot C, Teillac P, Demenais F, Mangin P, Cohen N, Le Duc A, Cussenot O. The PROGENE study, the French project of genetic analysis of familial prostatic cancer: recruitment and analysis. *Prog Urol*. 1996 Apr;6(2):226-35.

Cancer de la Vessie et des Voies Excrétrices Supérieures / Bladder & Upper Urinary Tract Cancer

1. Gabriel PE, Compérat E, Cancel-Tassin G, Varinot J, Roumiguié M, Patard PM, Daniel G, Pfister C, Delcourt C, Gobet F, Larré S, Léon P, Durlach A, Bigot P, Carrouget J, Eymerit C, Bessède T, Lebacle C, Ferlicot S, Ruffion A, Seizilles de Mazancourt E, Decaussin-Petrucci M, Crouzet S, Matillon X, Mège-Lechevallier F, Robert G, Vuong NS, Philip M, Lang H, Mouracade P, Lindner V, Cussenot O, Rouprêt M, Seisen T. Assessment of the Prognostic and Predictive Values of the Deficient Mismatch Repair Phenotype in Patients Treated with Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. *Eur Urol Oncol*. 2025 Aug;8(4):921-931. doi: 10.1016/j.euo.2025.03.014. Epub 2025 Apr 30. PMID: 40307090.
2. Gabriel PE, Cancel-Tassin G, Audenet F, Masson-Lecomte A, Allory Y, Roumiguié M, Pradère B, Lorient Y, Léon P, Traxer O, Xylinas E, Rouprêt M, Neuzillet Y, Seisen T. A collaborative review of the microsatellite instability/deficient mismatch repair phenotype in patients with upper tract urothelial carcinoma. *BJU Int*. 2024 Nov;134(5):723-735. doi: 10.1111/bju.16405. Epub 2024 May 30. PMID: 38813615.
3. Campedel L, Compérat E, Cancel-Tassin G, Varinot J, Pfister C, Delcourt C, Gobet F, Roumiguié M, Patard PM, Daniel G, Bigot P, Carrouget J, Eymerit C, Larré S, Léon P, Durlach A, Ruffion A, de Mazancourt ES, Decaussin-Petrucci M, Bessède T, Lebacle C, Ferlicot S, Robert G, Vuong NS, Philip M, Crouzet S, Matillon X, Mège-Lechevallier F, Lang H, Mouracade P, Lindner V, Gougis P, Cussenot O, Rouprêt M, Seisen T. Prognostic value of programmed death ligand-1 and programmed death-1 expression in patients with upper tract urothelial carcinoma. *BJU Int*. 2023 Nov;132(5):581-590. doi: 10.1111/bju.16129. Epub 2023 Aug 10. PMID: 37488983.
4. Koutros S, Kiemeny LA, Pal Choudhury P, Milne RL, Lopez de Maturana E, Ye Y, Joseph V, Florez-Vargas O, Dyrskjot L, Figueroa J, Dutta D, Giles GG, Hildebrandt MAT, Offit K, Kogevinas M, Weiderpass E, McCullough ML, Freedman ND, Albanes D, Kooperberg C, Cortessis VK, Karagas MR, Johnson A, Schwenn MR, Baris D, Furberg H, Bajorin DF, Cussenot O, Cancel-Tassin G, Benhamou S, Kraft P, Porru S, Carta A, Bishop T, Southey MC, Matullo G, Fletcher T, Kumar R, Taylor JA, Lamy P, Prip F, Kalisz M, Weinstein SJ, Hengstler JG, Selinski S, Harland M, Teo M, Kiltie AE, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Schned A, Lenz P, Riboli E, Brennan P, Tjønneland A, Otto T, Ovsiannikov D, Volkert F, Vermeulen SH, Aben KK, Galesloot TE, Turman C, De Vivo I, Giovannucci E, Hunter DJ, Hohensee C, Hunt R, Patel AV, Huang WY, Thorleifsson G, Gago-Dominguez M, Amiano P, Golka K, Stern MC; UROMOL Consortium; Yan W, Liu J, Li SA, Katta S, Hutchinson A, Hicks B, Wheeler WA, Purdue MP, McGlynn KA, Kitahara CM, Haiman CA, Greene MH, Rafnar T, Chatterjee N, Chanock SJ, Wu X, Real FX, Silverman DT, Garcia-Closas M, Stefansson K, Prokunina-Olsson L, Malats N, Rothman N. Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights. *Eur Urol*. 2023 Jul;84(1):127-137. doi: 10.1016/j.eururo.2023.04.020. Epub 2023 May 19. PMID: 37210288; PMCID: PMC10330197.
5. Michel F, Cancrini F, Cancel-Tassin G, Gamé X, Huyghe E, Rock A, Léon G, Uzan A, Desfemmes FR, Peyronnet B, Fallot J, Léon P, Rolland E, Perrouin-Verbe MA, Wodey J, Capon G, Karsenty G, Rouprêt M, Cussenot O, Alshehhi H, Comperat E, Phé V. A study of the immunohistochemical profile of bladder cancer in neuro- urological patients by the French Association of Urology. *World J Urol*. 2022 Feb 9. doi: 10.1007/s00345-022-03942-3. Epub ahead of print. PMID: 35138436.
6. Oszwald A, Wasinger G, Larnaudie L, Varinot J, Sebe P, Cussenot O, Compérat E. Pathological reporting of cystectomy lymph nodes: a retrospective analysis of experience in Paris. *World J Urol*. 2021 Nov;39(11):40294035. doi: 10.1007/s00345-021-03630-8. Epub 2021 Mar 20. PMID: 33743060; PMCID: PMC8571145.
7. Cancel-Tassin G, Roupret M, Pinar U, Gaffory C, Vanie F, Ondet V, Compérat E, Cussenot O. Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up. *World J Urol*. 2021 Sep;39(9):3329-3335. doi: 10.1007/s00345-021-03629-1. Epub 2021 Mar 26. PMID: 33770241; PMCID: PMC7994915.
8. Campedel L, Seisen T, Varinot J, Cancel-Tassin G, Ruffion A, De Mazancourt ES, Decaussin-Petrucci M, Robert G, Vuong NS, Philipp M, Compérat E, Rouprêt M, Cussenot O. Standardizing immunohistochemistry methodology for evaluation of PD-1 and PDL-1 expression in upper tract urothelial carcinoma. *Can J Urol*. 2021 Jun;28(3):10719-10724. PMID: 34129469.
9. Hoffman-Censits J, Choi W, Pal S, Trabulsi E, Kelly WK, Hahn NM, McConkey D, Comperat E, Matoso A, Cussenot O, Cancel-Tassin G, Fong MHY, Ross J, Madison R, Ali S. Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile. *Eur Urol Oncol*. 2021 Apr;4(2):297-300. doi: 10.1016/j.euo.2019.12.002. Epub 2020 Feb 13. PMID: 32061548.
10. Lenfant L, Cancel-Tassin G, Gazut S, Compérat E, Rouprêt M, Cussenot O. Genetic variability in 13q33 and 9q34 is linked to aggressiveness patterns and a higher risk of progression of non-muscle-invasive bladder cancer at the time of diagnosis. *BJU Int*. 2021 Mar;127(3):375-383. doi: 10.1111/bju.15254. Epub 2020 Oct 15. PMID: 32975901.

11. Cancel-Tassin G, Pinar U, Ciofu C, Ondet V, Gaffory C, Vanie F, Comperat E, Roupret M, Cussenot O. La performance du test urinaire Xpert® Bladder Cancer Monitor est supérieure à celle de la cytologie pour la détection des récidives des tumeurs de la vessie n'infiltrant pas le muscle. *Prog Urol.* 2020 Nov;30(13):790-791.
12. Hoffman-Censits J, Choi W, Pal S, Trabulsi E, Kelly WK, Hahn NM, McConkey D, Comperat E, Matoso A, Cussenot O, Cancel-Tassin G, Fong MHY, Ross J, Madison R, Ali S. Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile. *Eur Urol Oncol.* 2020 Feb 12:S2588-9311(19)30168-3.
13. Campedel L, Seisen T, Cussenot O, Comperat E, Varinot J, Rouprêt M, Cancel-Tassin G. Prognostic value of PD1/PD-L1 expression in upper tract urothelial carcinoma. *Prog Urol.* 2018 Dec;28(16):900-905.
14. Léon P, Cancel Tassin G, Sighar K, Compérat E, Gaffory C, Ondet V, Hugonin S, Audouin M, Doizi S, Traxer O, Ciofu C, Rouprêt M, Lacave R, Cussenot O. Correlation of genetic and cytogenetic alterations in pathological aggressiveness urothelial carcinoma of the bladder: Performance of BCA-1, amini-array comparative genomic hybridisation-based test. *Prog Urol.* 2017 Jun -Jul;27(8-9):451-457.
15. Figueroa JD, Middlebrooks CD, Banday AR, Ye Y, Garcia-Closas M, Chatterjee N, Koutros S, Kiemeny LA, Rafnar T, Bishop T, Furberg H, Matullo G, Golka K, Gago-Dominguez M, Taylor JA, Fletcher T, Siddiq A, Cortessis VK, Kooperberg C, Cussenot O, Benhamou S, Prescott J, Porru S, Dinney CP, Malats N, Baris D, Purdue MP, Jacobs EJ, Albanes D, Wang Z, Chung CC, Vermeulen SH, Aben KK, Galesloot TE, Thorleifsson G, Sulem P, Stefansson K, Kiltie AE, Harland M, Teo M, Offit K, Vijai J, Bajorin D, Kopp R, Fiorito G, Guarrera S, Sacerdote C, Selinski S, Hengstler JG, Gerullis H, Ovsianikov D, Blaszewicz M, Castelao JE, Calaza M, Martinez ME, Cordeiro P, Xu Z, Panduri V, Kumar R, Gurzau E, Koppova K, Bueno-De-Mesquita HB, Ljungberg B, Clavel-Chapelon F, Weiderpass E, Krogh V, Dorronsoro M, Travis RC, Tjønneland A, Brennan P, Chang-Claude J, Riboli E, Conti D, Stern MC, Pike MC, Van Den Berg D, Yuan JM, Hohensee C, Jeppson RP, Cancel-Tassin G, Roupret M, Comperat E, Turman C, De Vivo I, Giovannucci E, Hunter DJ, Kraft P, Lindstrom S, Carta A, Pavanello S, Arici C, Mastrangelo G, Kamat AM, Zhang L, Gong Y, Pu X, Hutchinson A, Burdett L, Wheeler WA, Karagas MR, Johnson A, Schned A, Monawar Hosain GM, Schwenn M, Kogevinas M, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Andriole G Jr, Grubb R 3rd, Black A, Diver WR, Gapstur SM, Weinstein S, Virtamo J, Haiman CA, Landi MT, Caporaso NE, Fraumeni JF Jr, Vineis P, Wu X, Chanock SJ, Silverman DT, Prokunina-Olsson L, Rothman N. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. *Hum Mol Genet.* 2016 Mar 15;25(6):1203-14.
16. Seisen T, Cancel-Tassin G, Colin P, Cussenot O, Rouprêt M. Carcinogenic pathways and natural history of upper tract urothelial carcinomas: state-of-the-art review for the yearly scientific report of the French National Association of Urology. *Prog Urol.* 2014 Nov;24(15):943-53.
17. Fu YP, Kohaar I, Moore LE, Lenz P, Figueroa JD, Tang W, Porter-Gill P, Chatterjee N, Scott-Johnson A, Garcia-Closas M, Muchmore B, Baris D, Paquin A, Ylaya K, Schwenn M, Apolo AB, Karagas MR, Tarway M, Johnson A, Mumy A, Schned A, Guede L, Jones MA, Kida M, Hosain GM, Malats N, Kogevinas M, Tardon A, Serra C, Carrato A, Garcia-Closas R, Lloreta J, Wu X, Purdue M, Andriole GL Jr, Grubb RL 3rd, Black A, Landi MT, Caporaso NE, Vineis P, Siddiq A, Bueno-de-Mesquita HB, Trichopoulos D, Ljungberg B, Severi G, Weiderpass E, Krogh V, Dorronsoro M, Travis RC, Tjønneland A, Brennan P, Chang-Claude J, Riboli E, Prescott J, Chen C, De Vivo I, Giovannucci E, Hunter D, Kraft P, Lindstrom S, Gapstur SM, Jacobs EJ, Diver WR, Albanes D, Weinstein SJ, Virtamo J, Kooperberg C, Hohensee C, Rodabough RJ, Cortessis VK, Conti DV, Gago-Dominguez M, Stern MC, Pike MC, Van Den Berg D, Yuan JM, Haiman CA, Cussenot O, Cancel-Tassin G, Roupret M, Comperat E, Porru S, Carta A, Pavanello S, Arici C, Mastrangelo G, Grossman HB, Wang Z, Deng X, Chung CC, Hutchinson A, Burdette L, Wheeler W, Fraumeni J Jr, Chanock SJ, Hewitt SM, Silverman DT, Rothman N, Prokunina-Olsson L. The 19q12 bladder cancer GWAS signal: association with cyclin E function and aggressive disease. *Cancer Res.* 2014 Oct 15;74(20):5808-18.
18. Figueroa JD, Han SS, Garcia-Closas M, Baris D, Jacobs EJ, Kogevinas M, Schwenn M, Malats N, Johnson A, Purdue MP, Caporaso N, Landi MT, Prokunina-Olsson L, Wang Z, Hutchinson A, Burdette L, Wheeler W, Vineis P, Siddiq A, Cortessis VK, Kooperberg C, Cussenot O, Benhamou S, Prescott J, Porru S, Bueno-de-Mesquita HB, Trichopoulos D, Ljungberg B, Clavel-Chapelon F, Weiderpass E, Krogh V, Dorronsoro M, Travis R, Tjønneland A, Brennan P, Chang-Claude J, Riboli E, Conti D, Gago-Dominguez M, Stern MC, Pike MC, Van Den Berg D, Yuan JM, Hohensee C, Rodabough R, Cancel-Tassin G, Roupret M, Comperat E, Chen C, De Vivo I, Giovannucci E, Hunter DJ, Kraft P, Lindstrom S, Carta A, Pavanello S, Arici C, Mastrangelo G, Karagas MR, Schned A, Armenti KR, Hosain GM, Haiman CA, Fraumeni JF Jr, Chanock SJ, Chatterjee N, Rothman N, Silverman DT. Genome-wide interaction study of smoking and bladder cancer risk. *Carcinogenesis.* 2014 Aug;35(8):1737-44.

19. Cussenot O, Sighar K, Mohammed M, Hugonin S, Ondet V, Larre S, Lacave R, Roupret M, Cancel-Tassin G. Detection of specific chromosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of non-muscle-invasive bladder transitional cell carcinoma. *World J Urol.* 2014 Apr;32(2):551-7.
20. Figueroa JD, Ye Y, Siddiq A, Garcia-Closas M, Chatterjee N, Prokunina-Olsson L, Cortessis VK, Kooperberg C, Cussenot O, Benhamou S, Prescott J, Porru S, Dinney CP, Malats N, Baris D, Purdue M, Jacobs EJ, Albanes D, Wang Z, Deng X, Chung CC, Tang W, Bas Bueno-de-Mesquita H, Trichopoulos D, Ljungberg B, Clavel-Chapelon F, Weiderpass E, Krogh V, Dorronsoro M, Travis R, Tjønneland A, Brenan P, Chang-Claude J, Riboli E, Conti D, Gago-Dominguez M, Stern MC, Pike MC, Van Den Berg D, Yuan JM, Hohensee C, Rodabough R, Cancel-Tassin G, Roupret M, Comperat E, Chen C, De Vivo I, Giovannucci E, Hunter DJ, Kraft P, Lindstrom S, Carta A, Pavanello S, Arici C, Mastrangelo G, Kamat AM, Lerner SP, Barton Grossman H, Lin J, Gu J, Pu X, Hutchinson A, Burdette L, Wheeler W, Kogevinas M, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Schwenn M, Karagas MR, Johnson A, Schned A, Armenti KR, Hosain GM, Andriole G Jr, Grubb R 3rd, Black A, Ryan Diver W, Gapstur SM, Weinstein SJ, Virtamo J, Haiman CA, Landi MT, Caporaso N, Fraumeni JF Jr, Vineis P, Wu X, Silverman DT, Chanock S, Rothman N. Genome-wide association study identifies multiple loci associated with bladder cancer risk. *Hum Mol Genet.* 2014 Mar 1;23(5):1387-98.
21. Compérat E, Jacquet SF, Varinot J, Conort P, Roupret M, Chartier-Kastler E, Bitker MO, Witjes JA, Cussenot O. Different subtypes of carcinoma in situ of the bladder do not have a different prognosis. *Virchows Arch.* 2013 Mar;462(3):343-8.
22. Yates DR, Rouprêt M, Drouin SJ, Audouin M, Cancel-Tassin G, Comperat E, Bitker MO, Cussenot O. Genetic polymorphisms on 8q24.1 and 4p16.3 are not linked with urothelial carcinoma of the bladder in contrast to their association with aggressive upper urinary tract tumours. *World J Urol.* 2013 Feb;31(1):53-9.
23. Scarpini S, Rouprêt M, Renard-Penna R, Camparo P, Cussenot O, Compérat E. Impact of the expression of AuroraA, p53, and MIB-1 on the prognosis of urothelial carcinomas of the upper urinary tract. *Urol Oncol.* 2012 Mar-Apr;30(2):182-7.
24. Audenet F, Traxer O, Yates DR, Cussenot O, Rouprêt M. Potential role of photodynamic techniques combined with new generation flexible ureterorenoscopes and molecular markers for the management of urothelial carcinoma of the upper urinary tract. *BJU Int.* 2012 Feb;109(4):608-13; discussion 613-4.
25. Rouprêt M, Drouin SJ, Cancel-Tassin G, Comperat E, Larré S, Cussenot O. Genetic variability in 8q24 confers susceptibility to urothelial carcinoma of the upper urinary tract and is linked with patterns of disease aggressiveness at diagnosis. *J Urol.* 2012 Feb;187(2):424-8.
26. Yates DR, Rouprêt M. Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy. *World J Urol.* 2011 Aug;29(4):415-22.
27. Phé V, Cussenot O, Bitker MO, Rouprêt M. Does the surgical technique for management of the distal ureter influence the outcome after nephroureterectomy? *BJU Int.* 2011 Jul;108(1):130-8.
28. Cornu JN, Merlet B, Cussenot O, Cancel-Tassin G, Ciofu C, Amarenco G, Haab F. Genetic susceptibility to urinary incontinence: implication of polymorphisms of androgen and oestrogen pathways. *World J Urol.* 2011 Apr;29(2):239-42.
29. Azémar MD, Comperat E, Richard F, Cussenot O, Rouprêt M. Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. *Urol Oncol.* 2011 Mar-Apr;29(2):130-6.
30. Larré S, Camparo P, Comperat E, Gil Diez De Medina S, Traxer O, Roupret M, Sebe P, Cancel-Tassin G, Sighar K, Lozach F, Cussenot O. Diagnostic, staging, and grading of urothelial carcinomas from urine: performance of BCA1, a mini-array comparative genomic hybridisation-based test. *Eur Urol.* 2011 Feb;59(2):250-7.
31. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, Real FX, Van Den Berg D, Matullo G, Baris D, Thun M, Kiemeny LA, Vineis P, De Vivo I, Albanes D, Purdue MP, Rafnar T, Hildebrandt MA, Kiltie AE, Cussenot O, Golka K, Kumar R, Taylor JA, Mayordomo JI, Jacobs KB, Kogevinas M, Hutchinson A, Wang Z, Fu YP, Prokunina-Olsson L, Burdett L, Yeager M, Wheeler W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G Jr, Grubb R 3rd, Black A, Jacobs EJ, Diver WR, Gapstur SM, Weinstein SJ, Virtamo J, Cortessis VK, Gago-Dominguez M, Pike MC, Stern MC, Yuan JM, Hunter DJ, McGrath M, Dinney CP, Czerniak B, Chen M, Yang H, Vermeulen SH, Aben KK, Witjes JA, Makkinje RR, Sulem P, Besenbacher S, Stefansson K, Riboli E, Brennan P, Panico S, Navarro C, Allen NE, Bueno-de-Mesquita HB, Trichopoulos D, Caporaso N, Landi MT, Canzian F, Ljungberg B, Tjønneland A, Clavel-Chapelon F, Bishop DT, Teo MT, Knowles MA, Guarrera S, Polidoro S, Ricceri F, Sacerdote C, Allione A, Cancel-Tassin G, Selinski S, Hengstler JG, Dietrich H, Fletcher T, Rudnai P, Gurzau E, Koppova K, Bolick SC, Godfrey A, Xu Z, Sanz-Velez JI, D GarcíaPrats M, Sanchez M, Valdivia G, Porru S, Benhamou S, Hoover RN, Fraumeni JF Jr, Silverman DT, Chanock SJ. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. *Nat Genet.* 2010 Nov;42(11):978-84.
32. Ouzaid I, Cussenot O, Rouprêt M. Prostate-sparing cystectomy for bladder cancer: a step toward a dead-end. *Urology.* 2010 Aug;76(2):260-3.

33. Cornu JN, Rouprêt M, Carpentier X, Geavlete B, de Medina SG, Cussenot O, Traxer O. Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. *World J Urol.* 2010 Apr;28(2):151-6.
34. Varinot J, Camparo P, Roupert M, Bitker MO, Capron F, Cussenot O, Witjes JA, Compérat E. Full analysis of the prostatic urethra at the time of radical cystoprostatectomy for bladder cancer: impact on final disease stage. *Virchows Arch.* 2009 Nov;455(5):449-53.
35. Phé V, Cussenot O, Rouprêt M. Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract. *BJU Int.* 2009 Oct;104(7):896-901.
36. van Oers JM, Zwarthoff EC, Rehman I, Azzouzi AR, Cussenot O, Meuth M, Hamdy FC, Catto JW. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. *Eur Urol.* 2009 Mar;55(3):650-7.
37. Rouprêt M, Hupertan V, Yates DR, Comperat E, Catto JW, Meuth M, Lackmichi A, Ricci S, Lacave R, Gattegno B, Richard F, Hamdy FC, Cussenot O. A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. *BJU Int.* 2008 Jun;101(11):1448-53.
38. Nicolle G, Comperat E, Nicolaïew N, Cancel-Tassin G, Cussenot O. Metastin (KISS-1) and metastin-coupled receptor (GPR54) expression in transitional cell carcinoma of the bladder. *Ann Oncol.* 2007 Mar;18(3):605-7.
39. Rouprêt M, Traxer O, Tligui M, Conort P, Chartier-Kastler E, Richard F, Cussenot O. Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection. *Eur Urol.* 2007 Mar;51(3):709-13; discussion 714.
40. Rouprêt M, Hupertan V, Traxer O, Loison G, Chartier-Kastler E, Conort P, Bitker MO, Gattegno B, Richard F, Cussenot O. Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. *Urology.* 2006 Jun;67(6):1181-7.
41. Rouprêt M, Cussenot O. Transitional cell carcinoma of the upper urinary tract new concepts in management. *Presse Med.* 2005 Apr 23;34(8):601-7.
42. Dumey N, Mongiat-Artus P, Devauchelle P, Lesourd A, Cotard JP, Le Duc A, Marty M, Cussenot O, Cohen Haguénauer O. In vivo retroviral mediated gene transfer into bladder urothelium results in preferential transduction of tumoral cells. *Eur Urol.* 2005 Feb;47(2):257-63.
43. Amira N, Cancel-Tassin G, Bernardini S, Cochand-Priollet B, Bittard H, Mangin P, Fournier G, Latil A, Cussenot O. Expression in bladder transitional cell carcinoma by real-time quantitative reverse transcription polymerase chain reaction array of 65 genes at the tumor suppressor locus 9q34.1-2: identification of 5 candidates tumor suppressor genes. *Int J Cancer.* 2004 Sep 10;111(4):539-42.
44. Catto JW, Azzouzi AR, Amira N, Rehman I, Feeley KM, Cross SS, Fromont G, Sibony M, Hamdy FC, Cussenot O, Meuth M. Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. *Oncogene.* 2003 Nov 27;22(54):8699-706.
45. Amira N, Rivet J, Soliman H, Cancel-Tassin G, Le Duc A, Janin A, Cussenot O. Microsatellite instability in urothelial carcinoma of the upper urinary tract. *J Urol.* 2003 Oct;170(4 Pt 1):1151-4.

Cancer du Rein / Kidney Cancer

1. Laskar RS, Muller DC, Li P, Machiela MJ, Ye Y, Gaborieau V, Foll M, Hofmann JN, Colli L, Sampson JN, Wang Z, Bacq-Daian D, Boland A, Abedi-Ardekani B, Durand G, Le Calvez-Kelm F, Robinot N, Blanche H, Prokhortchouk E, Skryabin KG, Burdett L, Yeager M, Radojevic-Skodric S, Savic S, Foretova L, Holcatova I, Janout V, Mates D, Rascu S, Mukeria A, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jinga V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Świątkowska B, Benhamou S, Cancel-Tassin G, Cussenot O, Trichopoulou A, Riboli E, Overvad K, Panico S, Ljungberg B, Sitaram RT, Giles GG, Milne RL, Severi G, Bruinsma F, Fletcher T, Koppova K, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Pharoah P, Andreotti G, Beane Freeman LE, Koutros S, Albanes D, Männistö S, Weinstein S, Clark PE, Edwards TL, Lipworth L, Carol H, Freedman ML, Pomerantz MM, Cho E, Kraft P, Preston MA, Wilson KM, Michael Gaziano J, Sesso HD, Black A, Freedman ND, Huang WY, Anema JG, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Teh BT, Peters U, White E, Anderson GL, Johnson L, Luo J, Chow WH, Moore LE, Choueiri TK, Wood C, Johansson M, McKay JD, Brown KM, Rothman N, Lathrop MG, Deleuze JF, Wu X, Brennan P, Chanock SJ, Purdue MP, Scelo G. Sex specific associations in genome wide association analysis of renal cell carcinoma. *Eur J Hum Genet.* 2019 Oct;27(10):1589-1598.
2. Johansson M, Carreras-Torres R, Scelo G, Purdue MP, Mariosa D, Muller DC, Timpson NJ, Haycock PC, Brown KM, Wang Z, Ye Y, Hofmann JN, Foll M, Gaborieau V, Machiela MJ, Colli LM, Li P, Garnier JG, Blanche H, Boland A, Burdette L, Prokhortchouk E, Skryabin KG, Yeager M, Radojevic-Skodric S, Ognjanovic S, Foretova L, Holcatova I, Janout V, Mates D, Mukeriya A, Rascu S, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jinga V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Benhamou S, Cancel-Tassin G, Cussenot O, Weiderpass E, Ljungberg B, Tumkur Sitaram R, Häggström C, Bruinsma F, Jordan SJ, Severi G, Winship I, Hveem K, Vatten LJ, Fletcher T, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Andreotti G, Beane Freeman LE, Koutros S, Männistö S, Weinstein S, Clark PE, Edwards TL, Lipworth L, Gapstur SM, Stevens VL, Carol H, Freedman ML, Pomerantz MM, Cho E, Wilson KM, Gaziano JM, Sesso HD, Freedman ND, Parker AS, Eckel-Passow JE, Huang WY, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Teh BT, Peters U, White E, Anderson GL, Johnson L, Luo J, Buring J, Lee IM, Chow WH, Moore LE, Eisen T, Henrion M, Larkin J, Barman P, Leibovich BC, Choueiri TK, Lathrop GM, Deleuze JF, Gunter M, McKay JD, Wu X, Houlston RS, Chanock SJ, Relton C, Richards JB, Martin RM, Davey Smith G, Brennan P. The influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization study. *PLoS Med.* 2019 Jan 3;16(1):e1002724.
3. Machiela MJ, Hofmann JN, Carreras-Torres R, Brown KM, Johansson M, Wang Z, Foll M, Li P, Rothman N, Savage SA, Gaborieau V, McKay JD, Ye Y, Henrion M, Bruinsma F, Jordan S, Severi G, Hveem K, Vatten LJ, Fletcher T, Koppova K, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Pharoah P, Andreotti G, Freeman LEB, Koutros S, Albanes D, Mannisto S, Weinstein S, Clark PE, Edwards TE, Lipworth L, Gapstur SM, Stevens VL, Carol H, Freedman ML, Pomerantz MM, Cho E, Kraft P, Preston MA, Wilson KM, Gaziano JM, Sesso HS, Black A, Freedman ND, Huang WY, Anema JG, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Colli LM, Sampson JN, Besse C, Blanche H, Boland A, Burdette L, Prokhortchouk E, Skryabin KG, Yeager M, Mijuskovic M, Ognjanovic M, Foretova L, Holcatova I, Janout V, Mates D, Mukeriya A, Rascu S, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jinga V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Szeszenia-Dabrowska N, Benhamou S, Cancel-Tassin G, Cussenot O, Bueno-de-Mesquita HB, Canzian F, Duell EJ, Ljungberg B, Sitaram RT, Peters U, White E, Anderson GL, Johnson L, Luo J, Buring J, Lee IM, Chow WH, Moore LE, Wood C, Eisen T, Larkin J, Choueiri TK, Lathrop GM, Teh BT, Deleuze JF, Wu X, Houlston RS, Brennan P, Chanock SJ, Scelo G, Purdue MP. Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. *Eur Urol.* 2017 Nov;72(5):747-754. Erratum in: *Eur Urol.* 2018 Sep;74(3):e85-e86.
4. Scelo G, Purdue MP, Brown KM, Johansson M, Wang Z, Eckel-Passow JE, Ye Y, Hofmann JN, Choi J, Foll M, Gaborieau V, Machiela MJ, Colli LM, Li P, Sampson JN, Abedi-Ardekani B, Besse C, Blanche H, Boland A, Burdette L, Chabrier A, Durand G, Le Calvez-Kelm F, Prokhortchouk E, Robinot N, Skryabin KG, Wozniak MB, Yeager M, Basta-Jovanovic G, Dzamic Z, Foretova L, Holcatova I, Janout V, Mates D, Mukeriya A, Rascu S, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jinga V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Szeszenia-Dabrowska N, Benhamou S, Cancel-Tassin G, Cussenot O, Baglietto L, Boeing H, Khaw KT, Weiderpass E, Ljungberg B, Sitaram RT, Bruinsma F, Jordan SJ, Severi G, Winship I, Hveem K, Vatten LJ, Fletcher T, Koppova K, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Pharoah P, Andreotti G, Freeman LEB, Koutros S, Albanes D, Männistö S, Weinstein S, Clark PE, Edwards TL, Lipworth L, Gapstur SM, Stevens VL, Carol H, Freedman ML, Pomerantz MM, Cho E, Kraft P, Preston MA, Wilson KM, Michael Gaziano J, Sesso HD, Black A, Freedman ND, Huang WY, Anema JG, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Teh BT, Peters U, White E, Anderson GL, Johnson L, Luo

- J,Buring J, Lee IM, Chow WH, Moore LE, Wood C, Eisen T, Henrion M, Larkin J, BarmanP, Leibovich BC, Choueiri TK, Mark Lathrop G, Rothman N, Deleuze JF, McKay JD, Parker AS, Wu X, Houlston RS, Brennan P, Chanock SJ. Genomewide association study identifies multiple risk loci for renal cell carcinoma. *Nat Commun*. 2017 Jun 9;8:15724.
5. Scelo G, Hofmann JN, Banks RE, Bigot P, Bhatt RS, Cancel-Tassin G, Chew SK, Creighton CJ, Cussenot O, Davis IJ, Escudier B, Frayling TM, Häggström C, Hildebrandt MA, Holcatova I, Johansson M, Linehan WM, McDermott DF, Nathanson KL, Ogawa S, Perlman EJ, Purdue MP, Stattin P, Swanton C, Vasudev NS, Wu X, Znaor A, Brennan P, Chanock SJ. International cancer seminars: a focus on kidney cancer. *Ann Oncol*. 2016 Aug;27(8):1382-5.
6. Malouf GG, Zhang J, Yuan Y, Compérat E, Rouprêt M, Cussenot O, Chen Y, Thompson EJ, Tannir NM, Weinstein JN, Valero V, Khayat D, Spano JP, Su X. Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. *Mol Oncol*. 2015 Jan;9(1):32-43.
7. Audenet F, Cancel-Tassin G, Bigot P, Audouin M, Gaffory C, Ondet V, Thibault F, Auribault K, Gazut S, Benhabiles N, Azzouzi AR, Méjean A, Rouprêt M, Cussenot O. Germline genetic variations at 11q13 and 12p11 locus modulate age at onset for renal cell carcinoma. *J Urol*. 2014 Feb;191(2):487-92.
8. Audenet F, Yates DR, Cancel-Tassin G, Cussenot O, Rouprêt M. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. *BJU Int*. 2012 Jun;109(12):1864-70.
9. Phé V, Yates DR, Renard-Penna R, Cussenot O, Rouprêt M. Is there a contemporary role for percutaneous needle biopsy in the era of small renal masses? *BJU Int*. 2012 Mar;109(6):867-72.
10. Wu X, Scelo G, Purdue MP, Rothman N, Johansson M, Ye Y, Wang Z, Zelenika D, Moore LE, Wood CG, Prokhortchouk E, Gaborieau V, Jacobs KB, Chow WH, Toro JR, Zaridze D, Lin J, Lubinski J, Trubicka J, SzeszeniaDabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Jinga V, Bencko V, Slamova A, Holcatova I, Navratilova M, Janout V, Boffetta P, Colt JS, Davis FG, Schwartz KL, Banks RE, Selby PJ, Harnden P, Berg CD, Hsing AW, Grubb RL 3rd, Boeing H, Vineis P, Clavel-Chapelon F, Palli D, Tumino R, Krogh V, Panico S, Duell EJ, Quirós JR, Sanchez MJ, Navarro C, Ardanaz E, Dorronsoro M, Khaw KT, Allen NE, Bueno-de-Mesquita HB, Peeters PH, Trichopoulos D, Linseisen J, Ljungberg B, Overvad K, Tjønneland A, Romieu I, Riboli E, Stevens VL, Thun MJ, Diver WR, Gapstur SM, Pharoah PD, Easton DF, Albanes D, Virtamo J, Vatten L, Hveem K, Fletcher T, Koppova K, Cussenot O, Cancel-Tassin G, Benhamou S, Hildebrandt MA, Pu X, Foglio M, Lechner D, Hutchinson A, Yeager M, Fraumeni JF Jr, Lathrop M, Skryabin KG, McKay JD, Gu J, Brennan P, Chanock SJ. A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. *Hum Mol Genet*. 2012 Jan 15;21(2):456-62.
11. Purdue MP, Johansson M, Zelenika D, Toro JR, Scelo G, Moore LE, Prokhortchouk E, Wu X, Kiemeny LA, Gaborieau V, Jacobs KB, Chow WH, Zaridze D, Matveev V, Lubinski J, Trubicka J, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Bucur A, Bencko V, Foretova L, Janout V, Boffetta P, Colt JS, Davis FG, Schwartz KL, Banks RE, Selby PJ, Harnden P, Berg CD, Hsing AW, Grubb RL 3rd, Boeing H, Vineis P, ClavelChapelon F, Palli D, Tumino R, Krogh V, Panico S, Duell EJ, Quirós JR, Sanchez MJ, Navarro C, Ardanaz E, Dorronsoro M, Khaw KT, Allen NE, Bueno-de-Mesquita HB, Peeters PH, Trichopoulos D, Linseisen J, Ljungberg B, Overvad K, Tjønneland A, Romieu I, Riboli E, Mukeria A, Shangina O, Stevens VL, Thun MJ, Diver WR, Gapstur SM, Pharoah PD, Easton DF, Albanes D, Weinstein SJ, Virtamo J, Vatten L, Hveem K, Njølstad I, Tell GS, Stoltenberg C, Kumar R, Koppova K, Cussenot O, Benhamou S, Oosterwijk E, Vermeulen SH, Aben KK, van der Marel SL, Ye Y, Wood CG, Pu X, Mazur AM, Boulygina ES, Chekanov NN, Foglio M, Lechner D, Gut I, Heath S, Blanche H, Hutchinson A, Thomas G, Wang Z, Yeager M, Fraumeni JF Jr, Skryabin KG, McKay JD, Rothman N, Chanock SJ, Lathrop M, Brennan P. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. *Nat Genet*. 2011 Jan;43(1):60-5.
12. Paule B, Bastien L, Deslandes E, Cussenot O, Podgorniak MP, Allory Y, Naïmi B, Porcher R, de La Taille A, Menashi S, Calvo F, Mourah S. Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. *PLoS One*. 2010 May 19;5(5):e10715.
13. Thibault F, Cancel-Tassin G, Cussenot O. Low penetrance genetic susceptibility to kidney cancer. *BJU Int*. 2006 Oct;98(4):735-8.
14. Valeri A, Cussenot O. Hereditary forms of kidney cancer and genetic screening. *Prog Urol*. 2003 Nov;13(5 Suppl 2):1201-4.